WO2024057237A1 - Lipid nanoparticles - Google Patents
Lipid nanoparticles Download PDFInfo
- Publication number
- WO2024057237A1 WO2024057237A1 PCT/IB2023/059101 IB2023059101W WO2024057237A1 WO 2024057237 A1 WO2024057237 A1 WO 2024057237A1 IB 2023059101 W IB2023059101 W IB 2023059101W WO 2024057237 A1 WO2024057237 A1 WO 2024057237A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- mol
- lnp
- amount
- present
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 313
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 32
- 239000002245 particle Substances 0.000 claims description 108
- 150000007523 nucleic acids Chemical class 0.000 claims description 105
- 102000039446 nucleic acids Human genes 0.000 claims description 98
- 108020004707 nucleic acids Proteins 0.000 claims description 98
- -1 cationic lipid Chemical class 0.000 claims description 96
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 95
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 78
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 claims description 72
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 claims description 70
- 229920001223 polyethylene glycol Polymers 0.000 claims description 57
- 108020004999 messenger RNA Proteins 0.000 claims description 51
- 239000002202 Polyethylene glycol Substances 0.000 claims description 44
- 235000012000 cholesterol Nutrition 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 26
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 18
- 150000002759 monoacylglycerols Chemical class 0.000 claims description 17
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 16
- 229940074096 monoolein Drugs 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000004698 Polyethylene Substances 0.000 claims description 9
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims description 8
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 6
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- QGWBEETXHOVFQS-UHFFFAOYSA-N 6-[6-(2-hexyldecanoyloxy)hexyl-(4-hydroxybutyl)amino]hexyl 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCO)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC QGWBEETXHOVFQS-UHFFFAOYSA-N 0.000 claims description 4
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- BPWFJNQUTKVHIR-UHFFFAOYSA-N 2-(2-methoxyethoxy)-N,N-di(tetradecyl)acetamide Chemical compound CCCCCCCCCCCCCCN(CCCCCCCCCCCCCC)C(=O)COCCOC BPWFJNQUTKVHIR-UHFFFAOYSA-N 0.000 claims description 2
- 108091079001 CRISPR RNA Proteins 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 238000010357 RNA editing Methods 0.000 claims description 2
- 230000026279 RNA modification Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010362 genome editing Methods 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 92
- 238000009472 formulation Methods 0.000 abstract description 54
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 35
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 27
- 229920001184 polypeptide Polymers 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 9
- 210000000056 organ Anatomy 0.000 abstract description 4
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 210000004962 mammalian cell Anatomy 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 45
- 125000002091 cationic group Chemical group 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 31
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 23
- 102000040430 polynucleotide Human genes 0.000 description 23
- 108091033319 polynucleotide Proteins 0.000 description 23
- 239000002157 polynucleotide Substances 0.000 description 23
- 239000000427 antigen Substances 0.000 description 22
- 230000007935 neutral effect Effects 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 229920000642 polymer Polymers 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 241000894007 species Species 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 150000003904 phospholipids Chemical class 0.000 description 14
- 150000003431 steroids Chemical class 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 229930182558 Sterol Natural products 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 235000003702 sterols Nutrition 0.000 description 13
- 238000012384 transportation and delivery Methods 0.000 description 13
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 150000003432 sterols Chemical class 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 238000005538 encapsulation Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 239000000084 colloidal system Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 229920006317 cationic polymer Polymers 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000001493 electron microscopy Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 7
- 235000013849 propane Nutrition 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000001294 propane Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000007327 Protamines Human genes 0.000 description 5
- 108010007568 Protamines Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 125000000129 anionic group Chemical group 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 230000002601 intratumoral effect Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229940048914 protamine Drugs 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 4
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 4
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- 208000002352 blister Diseases 0.000 description 4
- 238000001818 capillary gel electrophoresis Methods 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 4
- 239000008393 encapsulating agent Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 4
- 238000000235 small-angle X-ray scattering Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 3
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- NKHPSESDXTWSQB-WRBBJXAJSA-N 1-[3,4-bis[(z)-octadec-9-enoxy]phenyl]-n,n-dimethylmethanamine Chemical compound CCCCCCCC\C=C/CCCCCCCCOC1=CC=C(CN(C)C)C=C1OCCCCCCCC\C=C/CCCCCCCC NKHPSESDXTWSQB-WRBBJXAJSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 description 2
- PGYFLJKHWJVRMC-ZXRZDOCRSA-N 2-[4-[[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]butoxy]-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCCCOC(CN(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC)C1 PGYFLJKHWJVRMC-ZXRZDOCRSA-N 0.000 description 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 2
- XQYRNBOPIUSUMU-UHFFFAOYSA-M 2-aminoethyl-[2,3-di(tetradecoxy)propyl]-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCN)OCCCCCCCCCCCCCC XQYRNBOPIUSUMU-UHFFFAOYSA-M 0.000 description 2
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 description 2
- SLQKYSPHBZMASJ-QKPORZECSA-N 24-methylene-cholest-8-en-3β-ol Chemical compound C([C@@]12C)C[C@H](O)C[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@H]21 SLQKYSPHBZMASJ-QKPORZECSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- NYZTVPYNKWYMIW-WRBBJXAJSA-N 4-[[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-dimethylazaniumyl]methyl]benzoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)CC1=CC=C(C=C1)C([O-])=O)OC(=O)CCCCCCC\C=C/CCCCCCCC NYZTVPYNKWYMIW-WRBBJXAJSA-N 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- PESKGJQREUXSRR-UXIWKSIVSA-N 5alpha-cholestan-3-one Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 PESKGJQREUXSRR-UXIWKSIVSA-N 0.000 description 2
- PESKGJQREUXSRR-UHFFFAOYSA-N 5beta-cholestanone Natural products C1CC2CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 PESKGJQREUXSRR-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091027974 Mature messenger RNA Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- BGNVBNJYBVCBJH-UHFFFAOYSA-N SM-102 Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCC(OCCCCCCCCCCC)=O BGNVBNJYBVCBJH-UHFFFAOYSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 2
- NONFBHXKNNVFMO-UHFFFAOYSA-N [2-aminoethoxy(tetradecanoyloxy)phosphoryl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OP(=O)(OCCN)OC(=O)CCCCCCCCCCCCC NONFBHXKNNVFMO-UHFFFAOYSA-N 0.000 description 2
- HCAJCMUKLZSPFT-KWXKLSQISA-N [3-(dimethylamino)-2-[(9z,12z)-octadeca-9,12-dienoyl]oxypropyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC HCAJCMUKLZSPFT-KWXKLSQISA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229920006187 aquazol Polymers 0.000 description 2
- 239000012861 aquazol Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SLQKYSPHBZMASJ-UHFFFAOYSA-N bastadin-1 Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(C)CCC(=C)C(C)C)CCC21 SLQKYSPHBZMASJ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- HMFHBZSHGGEWLO-TXICZTDVSA-N beta-D-ribose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-TXICZTDVSA-N 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 2
- 235000004420 brassicasterol Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229930183167 cerebroside Natural products 0.000 description 2
- 150000001784 cerebrosides Chemical class 0.000 description 2
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 2
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 150000002313 glycerolipids Chemical class 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000002479 lipoplex Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 2
- JQRHOXPYDFZULQ-UHFFFAOYSA-N n,n-dimethyl-2,3-dioctadecoxypropan-1-amine Chemical compound CCCCCCCCCCCCCCCCCCOCC(CN(C)C)OCCCCCCCCCCCCCCCCCC JQRHOXPYDFZULQ-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- 229920000773 poly(2-methyl-2-oxazoline) polymer Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- LNGVIFNWQLYISS-KWXKLSQISA-N (12z,15z)-3-[(dimethylamino)methyl]-2-[(9z,12z)-octadeca-9,12-dienoyl]-4-oxohenicosa-12,15-dienamide Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)C(CN(C)C)C(C(N)=O)C(=O)CCCCCCC\C=C/C\C=C/CCCCC LNGVIFNWQLYISS-KWXKLSQISA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- KLFKZIQAIPDJCW-GPOMZPHUSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-GPOMZPHUSA-N 0.000 description 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- USPSDZQQNLMVMK-UHFFFAOYSA-N 1-Monolinolein Natural products CCCCCC=CC=CCCCCCCCC(=O)OCC(O)CO USPSDZQQNLMVMK-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-MDZDMXLPSA-N 1-[(9E)-octadecenoyl]glycerol Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-MDZDMXLPSA-N 0.000 description 1
- KVYUBFKSKZWZSV-FPLPWBNLSA-N 1-[(9Z)-hexadecenoyl]glycerol Chemical compound CCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO KVYUBFKSKZWZSV-FPLPWBNLSA-N 0.000 description 1
- BUOBCSGIAFXNKP-KWXKLSQISA-N 1-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylmethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CN(C)C)O1 BUOBCSGIAFXNKP-KWXKLSQISA-N 0.000 description 1
- RVHYPUORVDKRTM-UHFFFAOYSA-N 1-[2-[bis(2-hydroxydodecyl)amino]ethyl-[2-[4-[2-[bis(2-hydroxydodecyl)amino]ethyl]piperazin-1-yl]ethyl]amino]dodecan-2-ol Chemical compound CCCCCCCCCCC(O)CN(CC(O)CCCCCCCCCC)CCN(CC(O)CCCCCCCCCC)CCN1CCN(CCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CC1 RVHYPUORVDKRTM-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- ZXNAIPHYBVMMPY-KTKRTIGZSA-N 1-erucoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCC(O)CO ZXNAIPHYBVMMPY-KTKRTIGZSA-N 0.000 description 1
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical group O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 1
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- UZLHBUQJHDTDRD-UHFFFAOYSA-N 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium Chemical compound CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC UZLHBUQJHDTDRD-UHFFFAOYSA-N 0.000 description 1
- IUAUYSMYFCQVNW-UHFFFAOYSA-N 2,3-didodecoxy-n,n-dimethylpropan-1-amine Chemical compound CCCCCCCCCCCCOCC(CN(C)C)OCCCCCCCCCCCC IUAUYSMYFCQVNW-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- ARCRKLOZHGPFFJ-WAYWQWQTSA-N 2,3-dihydroxypropyl (z)-tetradec-9-enoate Chemical compound CCCC\C=C/CCCCCCCC(=O)OCC(O)CO ARCRKLOZHGPFFJ-WAYWQWQTSA-N 0.000 description 1
- LJARBVLDSOWRJT-UHFFFAOYSA-O 2-[2,3-di(pentadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCC LJARBVLDSOWRJT-UHFFFAOYSA-O 0.000 description 1
- GIEAGSSLJOPATR-TWCFUXPBSA-N 2-[8-[[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]octoxy]-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCCCCCCCOC(CN(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC)C1 GIEAGSSLJOPATR-TWCFUXPBSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- ASJSAQIRZKANQN-UHFFFAOYSA-N 2-deoxypentose Chemical compound OCC(O)C(O)CC=O ASJSAQIRZKANQN-UHFFFAOYSA-N 0.000 description 1
- JMOLZNNXZPAGBH-UHFFFAOYSA-M 2-hexyldecanoate Chemical compound CCCCCCCCC(C([O-])=O)CCCCCC JMOLZNNXZPAGBH-UHFFFAOYSA-M 0.000 description 1
- UPWGQKDVAURUGE-KTKRTIGZSA-N 2-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-KTKRTIGZSA-N 0.000 description 1
- HXVVOLDXHIMZJZ-UHFFFAOYSA-N 3-[2-[2-[2-[bis[3-(dodecylamino)-3-oxopropyl]amino]ethyl-[3-(dodecylamino)-3-oxopropyl]amino]ethylamino]ethyl-[3-(dodecylamino)-3-oxopropyl]amino]-n-dodecylpropanamide Chemical compound CCCCCCCCCCCCNC(=O)CCN(CCC(=O)NCCCCCCCCCCCC)CCN(CCC(=O)NCCCCCCCCCCCC)CCNCCN(CCC(=O)NCCCCCCCCCCCC)CCC(=O)NCCCCCCCCCCCC HXVVOLDXHIMZJZ-UHFFFAOYSA-N 0.000 description 1
- BGIOAQWKXAPFPH-UHFFFAOYSA-M 3-aminopropyl-(2,3-didodecoxypropyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCCCCCC BGIOAQWKXAPFPH-UHFFFAOYSA-M 0.000 description 1
- ZLCFGDAOIYFIPN-MJBGKLQRSA-M 3-aminopropyl-[2,3-bis[(z)-tetradec-9-enoxy]propyl]-dimethylazanium;bromide Chemical compound [Br-].CCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC\C=C/CCCC ZLCFGDAOIYFIPN-MJBGKLQRSA-M 0.000 description 1
- QNEMTSQNLVZHQO-UHFFFAOYSA-M 3-aminopropyl-[2,3-di(tetradecoxy)propyl]-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCCCCCCCC QNEMTSQNLVZHQO-UHFFFAOYSA-M 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KJHYUSLWTPMFTN-AQWUKCDYSA-N MG(18:1(11Z)/0:0/0:0) Chemical compound CCCCCC\C=C/CCCCCCCCCC(=O)OC[C@@H](O)CO KJHYUSLWTPMFTN-AQWUKCDYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- PFNFFQXMRSDOHW-UHFFFAOYSA-N Spermine Natural products NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- XYNPYHXGMWJBLV-VXPJTDKGSA-N Tomatidine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@@]11CC[C@H](C)CN1 XYNPYHXGMWJBLV-VXPJTDKGSA-N 0.000 description 1
- QMGSCYSTMWRURP-UHFFFAOYSA-N Tomatine Natural products CC1CCC2(NC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(O)C%10O)C8O)C(O)C7O QMGSCYSTMWRURP-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241001441550 Zeiformes Species 0.000 description 1
- NJFCSWSRXWCWHV-USYZEHPZSA-N [(2R)-2,3-bis(octadec-1-enoxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCC=COC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC=CCCCCCCCCCCCCCCCC NJFCSWSRXWCWHV-USYZEHPZSA-N 0.000 description 1
- DRAWQKGUORNASA-XPWSMXQVSA-N [2-hydroxy-3-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)COC(=O)CCCCCCC\C=C\CCCCCCCC DRAWQKGUORNASA-XPWSMXQVSA-N 0.000 description 1
- DSNRWDQKZIEDDB-UHFFFAOYSA-N [3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadec-9-enoyloxypropyl] octadec-9-enoate Chemical compound CCCCCCCCC=CCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCC=CCCCCCCCC DSNRWDQKZIEDDB-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229960003190 adenosine monophosphate Drugs 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- XRWMGCFJVKDVMD-UHFFFAOYSA-M didodecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC XRWMGCFJVKDVMD-UHFFFAOYSA-M 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- NRLNQCOGCKAESA-UHFFFAOYSA-N heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate Chemical compound CCCCCC=CCC=CCCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCCC=CCC=CCCCCC NRLNQCOGCKAESA-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000002423 hopanoids Chemical class 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- VLBPIWYTPAXCFJ-XMMPIXPASA-N lysophosphatidylcholine O-16:0/0:0 Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C VLBPIWYTPAXCFJ-XMMPIXPASA-N 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- XVUQPECVOGMPRU-ZPPAUJSGSA-N n,n-dimethyl-1,2-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC XVUQPECVOGMPRU-ZPPAUJSGSA-N 0.000 description 1
- OZBZDYGIYDRTBV-RSLAUBRISA-N n,n-dimethyl-1,2-bis[(9z,12z,15z)-octadeca-9,12,15-trienoxy]propan-1-amine Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/C\C=C/CC OZBZDYGIYDRTBV-RSLAUBRISA-N 0.000 description 1
- KHGRPHJXYWLEFQ-HKTUAWPASA-N n,n-dimethyl-2,3-bis[(9z,12z,15z)-octadeca-9,12,15-trienoxy]propan-1-amine Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/C\C=C/CC KHGRPHJXYWLEFQ-HKTUAWPASA-N 0.000 description 1
- ZVJAPVDDCYWINZ-UHFFFAOYSA-N n,n-dimethyl-2,3-di(tetradecoxy)propan-1-amine Chemical compound CCCCCCCCCCCCCCOCC(CN(C)C)OCCCCCCCCCCCCCC ZVJAPVDDCYWINZ-UHFFFAOYSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229940127066 new oral anticoagluant drug Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000002436 one-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 150000003135 prenol lipids Chemical class 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 150000003313 saccharo lipids Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- PWRIIDWSQYQFQD-UHFFFAOYSA-N sisunine Natural products CC1CCC2(NC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OC(CO)C(O)C(O)C9OC%10OC(CO)C(O)C(O)C%10O)C8O)C(O)C7O PWRIIDWSQYQFQD-UHFFFAOYSA-N 0.000 description 1
- 238000012607 small angle X-ray scattering experiment Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- XYNPYHXGMWJBLV-OFMODGJOSA-N tomatidine Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@]6(O[C@H]5C4)NC[C@@H](C)CC6)CC3)CC2)CC1 XYNPYHXGMWJBLV-OFMODGJOSA-N 0.000 description 1
- REJLGAUYTKNVJM-SGXCCWNXSA-N tomatine Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@@]1(NC[C@@H](C)CC1)O5)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O REJLGAUYTKNVJM-SGXCCWNXSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Definitions
- LNPs are effective drug delivery systems for biologically active compounds, such as therapeutic and/or prophylactic nucleic acids, proteins, and peptides, which are otherwise cell impermeable.
- nucleic acids which include large nucleic acid molecules such as, e.g., in vitro transcribed messenger RNA (mRNA) as well as smaller polynucleotides that interact with mRNA or a gene, need to be delivered to the proper cellular compartment to be effective.
- nucleic acids such as mRNA suffer from their physico-chemical properties that render them impermeable to cells.
- nucleic acids such as mRNA are rapidly degraded by nucleases present in blood and other fluids or in tissues and have been shown to stimulate strong immune responses in vitro and in vivo.
- Lipid nanoparticle formulations have improved nucleic acid delivery in vivo. For example, such formulations have significantly reduced siRNA doses necessary to achieve target knockdown in vivo (see Zimmermann et al., Nature 441: 111-114, 2006).
- lipid nanoparticle drug delivery systems are multi-component formulations comprising cationic lipids, helper (or structural) lipids, and lipids containing polyethylene glycol (PEG).
- the positively charged cationic lipids bind to the anionic nucleic acid, while the other components support a stable self-assembly of the lipid nanoparticles.
- LNPs non- cationic lipids
- helper lipids or “structural lipids”
- LNPs can form into an array of mesophases, including micelles, micellar cubic, hexagonal, bicontinuous cubic, lamellar, inversed bicontinuous cubic, inversed hexagonal, inversed micellar cubic and inversed micelle mesophases (see, e.g.
- LNPs The structural morphology of LNPs is considered an essential factor in how the encapsulated cargo is packaged and mediates fusion to the host cell where the cargo is ultimately released, and is the subject of ongoing research (e.g.
- Glyceryl monoolein is a structural lipid that has been used in forming LNP structures with cubic morphology (see, e.g. H. Kim & C. Leal, ACS Nano 9(10):10214- 10226 (2015)).
- Phytantriol is an aliphatic alcohol that is known to form cubic phases at physiological temperatures (see, e.g. Barauskas et al., Langmuir 19:9562-9565 (2003); “Final Report on the Safety Assessment of Phytantriol”, Int. J.
- LNPs lipid nanoparticles
- pharmaceutical compositions comprising the LNPs.
- the LNPs and pharmaceutical compositions are particularly useful for delivering a nucleic acid to a patient (e.g., a human) or to a cell.
- LNP formulations useful for the delivery of nucleic acids frequently employ a polymer- lipid conjugate, such as a PEG-lipid conjugate, which serves to help control particle size during LNP manufacture and prevent unwanted aggregation in the vial and in the blood after administration.
- the PEG-lipid conjugates also help to prevent unwanted opsonization in the blood.
- These PEG-lipid conjugates can use a PEG polymer component with a MW of about 2000.
- These PEG-lipid conjugates can be employed in molar ratios (relative to other lipids in the composition) of about 0.5% to about 10%.
- LNP formulations typically employ an ionizable lipid (such as a cationic lipid), and at least two structural lipids such as cholesterol and a phospholipid, such as distearoylphosphatidylcholine (DSPC).
- a cationic lipid such as a cationic lipid
- DSPC distearoylphosphatidylcholine
- lipid nanoparticle formulations described herein can contain at least one structural lipid selected from a monoacylglycerol and an aliphatic alcohol.
- LNP formulations described herein can contain an ionizable lipid (such as a cationic lipid), a polymer lipid conjugate (such as a PEG-lipid conjugate), and one or two structural lipids (such as cholesterol, glyceryl monoolein, or phytantriol).
- an ionizable lipid such as a cationic lipid
- a polymer lipid conjugate such as a PEG-lipid conjugate
- structural lipids such as cholesterol, glyceryl monoolein, or phytantriol
- lipid nanoparticles that comprise a nucleic acid, a cationic lipid, a polymer-lipid conjugate, such as a polyethylene glycol (PEG)- lipid conjugate, and at least one structural lipid selected from a monoacylglycerol and an aliphatic alcohol, such as glyceryl monoolein and phytantriol.
- the LNPs can comprise additional structural lipids such as sterols, phospholipids, and other structural lipids known in the art.
- the present disclosure further provides methods of using such LNPs to induce an immune response against a pathogen in a subject, such as a mammal (e.g. in a human); and/or to treat or prevent a disease, disorder, or condition in a subject, such as a mammal (e.g. in a human).
- a pathogen such as a mammal (e.g. in a human)
- a disease, disorder, or condition in a subject such as a mammal (e.g. in a human).
- one aspect of the present disclosure relates to the administration of a therapeutically effective amount of any of the LNPs described herein to a subject in need thereof for the treatment and/or prevention of a disease or disorder associated with coronaviruses, influenza, varicella zoster virus (shingles), respiratory syncytial virus, and other bacterial, fungal, or viral infections.
- the present disclosure relates to methods of inducing an effective immune response against a pathogen such as those noted herein in order to effectively prevent a disease or disorder in a subject caused by said pathogen, comprising administering an effective amount to said subject of any of the LNPs of the present disclosure.
- the present disclosure further provides LNPs that have a delayed release profile of the RNA contained therein as compared to LNPs that do not have a delayed release profile.
- CQAs critical quality attributes
- D show the RNA integrity.
- Figure 2. Representative cryo-electron micrographs of four LNPs, including A. standard DSPC: cholesterol (10:28.5 mol%), B. GMO 70 mol%, C. GMO: cholesterol 14.4:55.6 mol%, D. cholesterol: GMO 22:77 mol%, E. PHY 70 mol% and F PHY:GMO 14.4:55.6 mol%.
- a lipid nanoparticle comprising: (a) at least one nucleic acid; (b) at least one polymer-lipid conjugate in an amount from about 0.05 to about 5 mol% of the total lipid in the particle; (c) at least one cationic lipid in an amount from about 0.1 to about 50 mol% of the total lipid in the particle; and (d) at least one structural lipid selected from a monoacylglycerol and an aliphatic alcohol, wherein each of said at least one structural lipids is present in an amount from about 10 to about 99 mol% of the total lipid in the particle.
- LNP lipid nanoparticle
- the LNP of embodiment E1, wherein the at least one polymer-lipid conjugate is a polyethylene glycol (PEG)-lipid conjugate.
- PEG polyethylene glycol
- E7. The LNP of embodiment E2, wherein the PEG-lipid conjugate is selected from: dimyristoylphosphatidylcholine-polyethylene glycol-2000 (DMPC-PEG); 1,2- dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG); 1,2-dioleoyl- sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] ammonium salt (DOPE-PEG); 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-poly (ethylene glycol)-2000 (DSPE-PEG); mPEG-N,N-ditetradecylacetamide (ALC-0159); and oleoyl polyethylene glycol 2000.
- DMPC-PEG dimy
- E8 The LNP of embodiment E1, wherein the at least one cationic lipid is present in an amount from about 0.5 to about 40 mol% of the total lipid in the particle.
- E9. The LNP of embodiment E1, wherein the at least one cationic lipid is present in an amount from about 1 to about 35 mol% of the total lipid in the particle.
- E10. The LNP of embodiment E1, wherein the at least one cationic lipid is present in an amount from about 5 to about 30 mol% of the total lipid in the particle.
- E11 The LNP of embodiment E1, wherein the at least one cationic lipid is present in an amount from about 10 to about 20 mol% of the total lipid in the particle.
- the LNP of embodiment E1, wherein the at least one cationic lipid is selected from: (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4- (dimethylamino)butanoate (Dlin-MC3-DMA); [(4-hydroxybutyl)azanediyl]di(hexane- 6,1-diyl) bis(2-hexyldecanoate) (ALC-0315); 2-[2,2-bis[(9Z,12Z)-octadeca-9,12- dienyl]-1,3-dioxolan-4-yl]-N,N-dimethylethanamine (DLin-KC2-DMA); 1,2- dilinoleyloxy-n,n-dimethyl-3-aminopropane (DLinDMA); N,N-dimethyl-2,3-bis[(Z)- octade
- E13 The LNP of embodiment E12, wherein the at least one cationic lipid is Dlin-MC3-DMA.
- E14. The LNP of embodiment E1, wherein the at least one structural lipid is glyceryl monoolein (GMO).
- GMO glyceryl monoolein
- E15. The LNP of embodiment E14, wherein GMO is present in an amount from about 10 to about 99 mol% of the total lipid in the particle.
- E16 The LNP of embodiment E14, wherein GMO is present in an amount from about 20 to about 90 mol% of the total lipid in the particle.
- E17. The LNP of embodiment E14, wherein GMO is present in an amount from about 30 to about 80 mol% of the total lipid in the particle.
- E19. The LNP of embodiment E14, wherein GMO is present in an amount from about 50 to about 60 mol% of the total lipid in the particle.
- E20. The LNP of embodiment E14, wherein GMO is present in an amount from about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90 or about 99 mol% of the total lipid in the particle.
- the LNP of embodiment E1 wherein the at least one structural is phytantriol (PHY).
- E28. The LNP of embodiment E1, comprising at least one monoacylglycerol structural lipid and at least one aliphatic alcohol structural lipid.
- E29. The LNP of embodiment E28, wherein the monoacylglycerol is GMO.
- E30. The LNP of embodiment E28, wherein the aliphatic alcohol is PHY.
- the LNP of embodiment E28, wherein the monoacylglycerol is GMO, and the aliphatic alcohol is PHY.
- E33. The LNP of embodiment E1, further comprising at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol, wherein said at least one additional structural lipid is present in an amount from about 10 to about 75 mol% of the total lipid present in the particle.
- E34. The LNP of embodiment E33, wherein said at least one additional structural lipid is a sterol.
- E36. The LNP of embodiment E33, wherein said at least one additional structural lipid is a phospholipid.
- E37 The LNP of embodiment E36, wherein said phospholipid is distearoylphosphatidylcholine (DSPC).
- E38. The LNP of embodiment E35, wherein cholesterol is present in an amount from about 10 to about 75 mol% of the total lipid present in the particle.
- E39. The LNP of embodiment E37, wherein DSPC is present in an amount from about 10 to about 75 mol% of the total lipid present in the particle.
- the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 14.4 mol%; the at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol is cholesterol and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DOPE- PEG and is present in an amount of about 1.5 mol%.
- the at least one cationic lipid is present in an amount of about 1.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 77 mol%; the at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol is cholesterol and is present in an amount of about 20 mol%; and the at least one polymer-lipid conjugate is DOPE- PEG and is present in an amount of about 1.5 mol%.
- the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 14.4 mol%; a second structural lipid is PHY and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DOPE-PEG and is present in an amount of about 1.5 mol%.
- the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is PHY and is present in an amount of about 14.4 mol%; a second structural lipid is GMO and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DMG-PEG and is present in an amount of about 1.5 mol%.
- the at least one cationic lipid is present in an amount of about 28.5 mol%
- the at least one structural lipid is PHY and is present in an amount of about 14.4 mol%
- a second structural lipid is GMO and is present in an amount of about 55.6 mol%
- the at least one polymer-lipid conjugate is DMG-PEG and is present in an amount of about 1.5 mol%.
- the LNP of embodiment E1 wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 70 mol%; and the at least one polymer-lipid conjugate is DOPE-PEG and is present in an amount of about 1.5 mol%.
- E46. The LNP of any one of embodiments E1-E45, wherein the particle size of the LNP is less than about 500 nm.
- E47. The LNP of embodiment E46, wherein the particle size of the LNP is from about 20 to about 500 nm.
- the LNP of embodiment E47, wherein the particle size of the LNP is from about 20 to about 300 nm. E49.
- the LNP of embodiment E48, wherein the particle size of the LNP is from about 20 to about 200 nm.
- the LNP of embodiment E49, wherein the particle size of the LNP is from about 20 to about 150 nm.
- the LNP of embodiment E50, wherein the particle size of the LNP is from about 20 to about 100 nm.
- the LNP of embodiment E49, wherein the particle size of the LNP is about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, or about 200 nm.
- a composition comprising the LNPs of any one of embodiments E1-E45, wherein the average particle size of the LNPs is less than about 500 nm.
- E57. The composition of embodiment E56, wherein the average particle size of the LNPs is from about 20 to about 150 nm.
- composition of embodiment E57 wherein the average particle size of the LNPs is from about 20 to about 100 nm.
- E59. The composition of embodiment E56, wherein the average particle size of the LNPs is about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, or about 200 nm.
- a pharmaceutical composition comprising the LNP of any one of embodiments of E1-E45, and a pharmaceutically acceptable carrier.
- composition of embodiment E62 which is formulated for intravenous, intramuscular, subcutaneous, intratumoral, intranasal, or inhalation administration.
- E64. A method for delivering a nucleic acid to a cell comprising contacting the cell with the LNP of any one of embodiments E1-E45, or E60-E61.
- E65. A method for delivering a nucleic acid of interest to a subject comprising administering to the subject at least one dose of the composition of embodiment E62.
- E66. The method of embodiment E65, wherein the nucleic acid is mRNA that encodes at least one protein of interest.
- E67. The method of embodiment E66, wherein the at least one protein of interest is a therapeutic protein.
- the at least one protein of interest is a vaccine antigen.
- E69. A method for treating a disease characterized by a genetic defect that results in a deficiency of a functional protein, the method comprising: administering to a subject having the disease, the LNP of embodiment E66, wherein the mRNA encodes the functional protein or a protein having the same biological activity as the functional protein.
- E70. A method for inducing an immune response against a pathogen in a subject comprising administering to the subject the LNP of embodiment E66, wherein the mRNA encodes a protein antigen from said pathogen, or an immunogenic variant or fragment thereof.
- E72. The LNP of any one of embodiments E1-E45, for the therapeutic or prophylactic treatment of a disease characterized by overexpression of a polypeptide.
- E73. The LNP of any one of embodiments E1-E45, for the prophylactic treatment of a disease caused by a pathogen. Definitions Throughout this application, the term “about” is used according to its plain and ordinary meaning in the area of lipid chemistry and formulations to indicate a deviation of ⁇ 10% of the value(s) to which it is attached.
- A, B, and/or C includes: A alone, B alone, C alone, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C.
- administer describes the introduction of the relevant LNP or composition to a subject, such as a mammal (e.g. a human) by a particular route or vehicle.
- Routes of administration may include, but are not limited to, topical, parenteral and enteral which include oral, buccal, sub- lingual, nasal, anal, gastrointestinal, subcutaneous, intramuscular and intradermal routes of administration.
- treat describes the administration of the relevant LNP or composition to a subject, such as a mammal (e.g.
- a human to at least ameliorate, reduce or suppress existing signs or symptoms of a disease, disorder or condition experienced by the subject, to the extent that the medical condition is improved according to clinically acceptable standard(s).
- to treat a bacterial infection means to reduce the infection, or eradicate the infection, or relieve symptoms of the infection in a subject, wherein the improvement and relief are evaluated with a clinically acceptable standardized test and/or an empirical test, including swab sample testing and the like.
- the terms “prevent”, “preventing” or “preventative” mean prophylactically administering the relevant LNP or composition to a subject, such as a mammal (e.g.
- an effective amount or “therapeutically effective amount” refers to the administration of an amount of the relevant particle or composition sufficient to prevent the occurrence of symptoms of the condition being treated, or to bring about a halt in the worsening of symptoms or to treat and alleviate or at least reduce the severity of the symptoms. The effective amount will vary in a manner which would be understood by a person of skill in the art with patient age, sex, weight etc.
- an appropriate dosage or dosage regime can be ascertained through routine trial or based on current treatment regimes for the active being delivered via an LNP of the present disclosure.
- the terms "subject” or “individual” or “patient” may refer to any subject, particularly a vertebrate subject, and even more particularly a mammalian subject, for whom therapy is desired.
- Suitable vertebrate animals include, but are not restricted to, primates, avians, livestock animals (e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and captive wild animals (e.g., foxes, deer, dingoes).
- livestock animals e.g., sheep, cows, horses, donkeys, pigs
- laboratory test animals e.g., rabbits, mice, rats, guinea pigs, hamsters
- companion animals e.g., cats, dogs
- captive wild animals e.g., foxes, deer, dingoes.
- a preferred subject is a human in need of treatment for a disease, disorder or condition as described herein. However, it will be understood that the aforementioned terms do not imply that symptoms are necessarily present.
- a nucleic acid molecule is a polymer comprising or consisting of nucleotide monomers, which are covalently linked to each other by phosphodiester-bonds of a sugar/phosphate-backbone.
- Nucleic acids may also encompass modified nucleic acid molecules, such as, for example, base-modified, sugar-modified or backbone-modified DNA or RNA molecules.
- Nucleic acids can exist in a variety of forms such as: isolated segments and recombinant vectors of incorporated sequences or recombinant polynucleotides encoding polypeptides, such as antigens or one or both chains of an antibody, or a fragment, derivative, mutein, or variant thereof, polynucleotides sufficient for use as hybridization probes, PCR primers or sequencing primers for identifying, analyzing, mutating or amplifying a polynucleotide encoding a polypeptide, anti-sense nucleic acids for inhibiting expression of a polynucleotide, mRNA, saRNA, and complementary sequences of the foregoing described herein.
- Nucleic acids can be single-stranded or double-stranded and can comprise RNA and/or DNA nucleotides and artificial variants thereof (e.g., peptide nucleic acids).
- a nucleic acid sequence may encode a polypeptide sequence with additional heterologous coding sequences, for example to allow for purification of the polypeptide, transport, secretion, post-translational modification, or for therapeutic benefits such as targeting or efficacy.
- a tag or other heterologous polypeptide may be added to the modified polypeptide-encoding sequence, wherein “heterologous” refers to a polypeptide that is not the same as the modified polypeptide.
- polynucleotide refers to a nucleic acid molecule that can be recombinant or has been isolated from total genomic nucleic acid. Included within the term “polynucleotide” are oligonucleotides (nucleic acids that are 100 residues or less in length), recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like. Polynucleotides include, in certain aspects, regulatory sequences, isolated substantially away from their naturally occurring genes or protein encoding sequences.
- Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be RNA, DNA (genomic, cDNA, or synthetic), analogs thereof, or a combination thereof. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide.
- polynucleotide variants having substantial identity to the sequences disclosed herein; those comprising equal to any one of, at least any one of, at most any one of, or between any two of 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity, compared to a polynucleotide sequence provided herein using the methods described herein (e.g., BLAST analysis using standard parameters).
- the isolated polynucleotide will comprise a nucleotide sequence encoding a polypeptide that has at least 90% identity to an amino acid sequence described herein, over the entire length of the sequence; or a nucleotide sequence complementary to said isolated polynucleotide. In some aspects, the isolated polynucleotide will comprise a nucleotide sequence encoding a polypeptide that has at least 95% identity to an amino acid sequence described herein, over the entire length of the sequence; or a nucleotide sequence complementary to said isolated polynucleotide.
- nucleic acid segments regardless of the length of the coding sequence itself, may be combined with other nucleic acid sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably.
- the nucleic acids can be any length.
- nucleotides in length can comprise one or more additional sequences, for example, regulatory sequences, and/or be a part of a larger nucleic acid, for example, a vector.
- nucleic acid fragment of almost any length may be employed, with the total length being limited by the ease of preparation and use in the intended recombinant nucleic acid protocol.
- gene is used to refer to a nucleic acid that encodes a protein, polypeptide, or peptide (including any sequences required for proper transcription, post-translational modification, or localization).
- this term encompasses genomic sequences, expression cassettes, cDNA sequences, and smaller engineered nucleic acid segments that express, or may be adapted to express, proteins, polypeptides, domains, peptides, fusion proteins, and mutants.
- a nucleic acid encoding all or part of a polypeptide may contain a contiguous nucleic acid sequence encoding all or a portion of such a polypeptide. It also is contemplated that a particular polypeptide may be encoded by nucleic acids containing variations having slightly different nucleic acid sequences but, nonetheless, encode the same or substantially similar polypeptide.
- expression of a nucleic acid sequence refers to the generation of any gene product from the nucleic acid sequence.
- a gene product can be a transcript.
- a gene product can be a polypeptide.
- expression of a nucleic acid sequence involves one or more of the following: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, etc.); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
- engineered refers to the aspect of having been manipulated by the hand of man.
- a polynucleotide is considered to be “engineered” when two or more sequences that are not linked together in that order in nature are manipulated by the hand of man to be directly linked to one another in the engineered polynucleotide and/or when a particular residue in a polynucleotide is non- naturally occurring and/or is caused through action of the hand of man to be linked with an entity or moiety with which it is not linked in nature.
- DNA means a nucleic acid molecule comprising nucleotides such as deoxy-adenosine-monophosphate, deoxy-thymidine- monophosphate, deoxy-guanosine-monophosphate and deoxy-cytidine- monophosphate monomers which are composed of a sugar moiety (deoxyribose), a base moiety and a phosphate moiety, and polymerize by a characteristic backbone structure.
- the backbone structure is, typically, formed by phosphodiester bonds between the sugar moiety of the nucleotide, i.e. deoxyribose, of a first and a phosphate moiety of a second, adjacent monomer.
- DNA sequence The specific order of the monomers, i.e. the order of the bases linked to the sugar/phosphate-backbone, is called the DNA sequence.
- DNA may be single stranded or double stranded. In the double stranded form, the nucleotides of the first strand typically hybridize with the nucleotides of the second strand, e.g. by A/T-base-pairing and G/C-base-pairing.
- DNA can contain all, or a majority of, deoxyribonucleotide residues.
- deoxyribonucleotide means a nucleotide lacking a hydroxyl group at the 2′ position of a ⁇ -D-ribofuranosyl group.
- DNA can encompass double stranded DNA, antisense DNA, single stranded DNA, isolated DNA, synthetic DNA, DNA that is recombinantly produced, and modified DNA.
- RNA means a nucleic acid molecule comprising nucleotides such as adenosine-monophosphate, uridine-monophosphate, guanosine- monophosphate and cytidine-monophosphate monomers which are connected to each other along a so-called backbone.
- the backbone is formed by phosphodiester bonds between the sugar, i.e. ribose, of a first and a phosphate moiety of a second, adjacent monomer.
- RNA may be obtainable by transcription of a DNA-sequence, e.g., inside a cell. In eukaryotic cells, transcription is typically performed inside the nucleus or the mitochondria. In vivo, transcription of DNA may result in premature RNA which is processed into messenger-RNA (mRNA). Processing of the premature RNA, e.g. in eukaryotic organisms, comprises various posttranscriptional modifications such as splicing, 5′ capping, polyadenylation, export from the nucleus or the mitochondria. Mature messenger RNA is processed and provides the nucleotide sequence that may be translated into an amino acid sequence of a peptide or protein.
- mRNA messenger-RNA
- a mature mRNA may comprise a 5′ cap, a 5′ UTR, an open reading frame, a 3′ UTR and a poly-A tail sequence.
- RNA can contain all, or a majority of, ribonucleotide residues.
- ribonucleotide means a nucleotide with a hydroxyl group at the 2′ position of a ⁇ -D-ribofuranosyl group.
- RNA can be messenger RNA (mRNA) that relates to a RNA transcript which encodes a peptide or protein.
- RNA generally contains a 5′ untranslated region (5′ UTR), a polypeptide coding region, and a 3′ untranslated region (3′ UTR).
- RNA can encompass double stranded RNA, antisense RNA, single stranded RNA, isolated RNA, synthetic RNA, RNA that is recombinantly produced, and modified RNA (modRNA).
- modified RNA modified RNA
- An “isolated RNA” is defined as an RNA molecule that can be recombinant or has been isolated from total genomic nucleic acid.
- An isolated RNA molecule or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.
- modified RNA refers to an RNA molecule having at least one addition, deletion, substitution, and/or alteration of one or more nucleotides as compared to naturally occurring RNA. Such alterations can refer to the addition of non- nucleotide material to internal RNA nucleotides, or to the 5′ and/or 3′ end(s) of RNA.
- such modRNA contains at least one modified nucleotide, such as an alteration to the base of the nucleotide.
- a modified nucleotide can replace one or more uridine and/or cytidine nucleotides.
- these replacements can occur for every instance of uridine and/or cytidine in the RNA sequence, or can occur for only select uridine and/or cytidine nucleotides.
- Such alterations to the standard nucleotides in RNA can include non-standard nucleotides, such as chemically synthesized nucleotides or deoxynucleotides.
- at least one uridine nucleotide can be replaced with 1-methylpseudouridine in an RNA sequence.
- Other such altered nucleotides are known to those of skill in the art.
- Such altered RNAs are considered analogs of naturally-occurring RNA.
- the RNA is produced by in vitro transcription using a DNA template, where DNA refers to a nucleic acid that contains deoxyribonucleotides.
- the RNA can be replicon RNA (replicon), in particular self-replicating RNA, or self-amplifying RNA (saRNA).
- replicon RNA
- saRNA self-amplifying RNA
- Methods described herein comprise administration of the RNA described herein to a mammal, such as a human.
- RNA examples include an antigen-coding RNA vaccine to induce robust neutralizing antibodies and accompanying/concomitant T-cell response to achieve protective immunization.
- minimal vaccine doses are administered to induce robust neutralizing antibodies and accompanying/concomitant T-cell response to achieve protective immunization.
- the RNA administered is in vitro transcribed RNA.
- such RNA can be used to encode at least one antigen intended to generate an immune response in said mammal.
- Pathogenic antigens are peptide or protein antigens derived from a pathogen associated with infectious disease.
- antigen may refer to a substance, which is capable of being recognized by the immune system, e.g., by the adaptive immune system, and which is capable of eliciting an antigen-specific immune response, e.g. by formation of antibodies and/or antigen-specific T cells as part of an adaptive immune response.
- An antigen may be or may comprise a peptide or protein, which may be presented by the MHC to T-cells.
- An antigen may be the product of translation of a provided nucleic acid molecule, e.g., an RNA molecule comprising at least one coding sequence as described herein.
- lipid refers to a chemical compound that is insoluble in water and extractable with an organic solvent. Lipids may be naturally occurring, or synthetic. Typically, a lipid is a biological compound. Compounds other than those specifically described herein are understood by one of skill in the art as lipids, and are encompassed by the compositions and methods of the present disclosure. A lipid component and a non-lipid may be attached to one another, either covalently or non- covalently.
- lipid nanoparticle refers to particles of any morphology generated when a cationic lipid and optionally one or more further lipids are combined, e.g. in an aqueous environment and/or in the presence of a nucleic acid such as RNA.
- lipid nanoparticles are included in a formulation that can be used to deliver an active agent or therapeutic agent, such as a nucleic acid (e.g., mRNA) to a target site of interest (e.g., cell, tissue, organ, tumor, and the like).
- a nucleic acid e.g., mRNA
- the lipid nanoparticles of the present disclosure comprise a nucleic acid.
- Such lipid nanoparticles typically comprise a cationic lipid and one or more excipients, e.g., one or more neutral lipids, charged lipids, steroids, polymer conjugated lipids, or combinations thereof.
- the active agent or therapeutic agent such as a nucleic acid (e.g., mRNA)
- a nucleic acid e.g., mRNA
- the nucleic acid e.g., mRNA
- a lipid nanoparticle may comprise any lipid capable of forming a particle to which the nucleic acids are attached, or in which the one or more nucleic acids are encapsulated.
- the LNPs disclosed herein typically have a mean diameter of from about 1 nm to about 500 nm.
- mean diameter refers to the mean hydrodynamic diameter of particles as measured by dynamic laser light scattering (DLS) with data analysis using the so-called cumulant algorithm, which provides as results the so-called Z-average with the dimension of a length, and the polydispersity index (PI), which is dimensionless (Koppel, D., J.
- polymer-lipid conjugate refers to a molecule comprising both a lipid portion and a polymer portion.
- An example of a polymer-lipid conjugate is a pegylated lipid.
- pegylated lipid (PEG lipid) refers to a molecule comprising both a lipid portion and a polyethylene glycol portion.
- Pegylated lipids are known in the art and include lipids such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-s-DMG), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, poly- ethylene glycol conjugated lipids in C14-C18 range, i.e.
- DMPC-PEG (Dimyristoylphosphatidylcholine-polyethylene glycol-2000), DMG-PEG (1,2- dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000), DOPE-PEG (1,2- dioleoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] ammonium salt), DSPE-PEG (1, 2-Distearoyl-sn-glycero-3-phosphoethanolamine- Poly (ethylene glycol)-2000), ALC-0159, oleoyl polyethylene glycol 2000, and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol), and the like.
- polymer-lipid conjugates include polyoxazolines, poly (2- methyl-2-oxazoline) (PMOZ), poly (2-ethyl-2-oxazoline) (PEOZ), polysarcosines, polyglycerol polymer conjugates (i.e. PG-30), and polycarbonate polymer conjugates (i.e. PCs) and the like.
- a "cationic lipid” refers to a lipid or lipid like material having a net positive charge. Cationic lipids bind negatively charged nucleic acid by electrostatic interaction.
- cationic lipids possess a lipophilic moiety, such as a sterol, an acyl chain, a diacyl or more acyl chains, and the head group of the lipid typically carries the positive charge.
- exemplary cationic lipids include one or more amine group(s) which bear the positive charge.
- Cationic lipids may encapsulate negatively charged RNA.
- cationic lipids are ionizable such that they can exist in a positively charged or neutral form depending on pH. The ionization of the cationic lipid affects the surface charge of the lipid nanoparticle under different pH conditions.
- examples of cationic lipids include Dlin-MC3-DMA ((6Z,9Z,28Z,31Z)-Heptatriaconta-6,9,28,31- tetraen-19-yl 4-(dimethylamino)butanoate), ALC-0315 ([(4- hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate)), DLin-KC2-DMA (2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-N,N- dimethylethanamine), DLinDMA (1,2-dilinoleyloxy-n,n-dimethyl-3-aminopropane), DODMA (N,N-dimethyl-2,3-bis[(Z)-octadec-9-enoxy
- a “structural lipid” is a lipid that helps stabilize the formation of LNPs during their formation, and can mediate the morphology of an LNP.
- Such structural lipids include non-cationic lipids, e.g., neutral lipids and anionic lipids (e.g. phospholipids).
- examples of structural lipids include monoacyglycerols, aliphatic alcohols, and sterols.
- optimizing the formulation of LNPs by addition of such structural lipids in addition to a cationic lipid may enhance particle stability and efficacy of nucleic acid delivery.
- the terms “monoacylglycerol” and “aliphatic alcohol” are classes of chemical compounds known to those in the art, and can include, without limitation, monoolein, 2-monoolein, citrem, oleoyl lactate, oleamide, monoelaidin, linoleic acid, monomyristolein, elaidic acid, glyceryl monoolein (GMO), monopalmitolein, monolinolein, monovaccenin, monoerucin, phytantriol (PHY), diolein, triolein, dioleoyl-glycerol, didodecyldimethylammonium bromide, dioctadecyl (dimethyl) ammonium chloride (DOAC/DODMAC) and dimethyldioctadecylammonium bromide (DODAB).
- phospholipid is any lipid that comprises a phosphate group.
- Phospholipids are a subset of non-cationic lipids.
- examples of phospholipids include 1, 2- Dioleoyl-phosphatidic acid (DOPA), 1, 2-Dioleoyl- phosphatidylglycerol (DOPG), 1, 2- Distearoyl-phophatidylglycerol (DSPG), 1, 2- Dioleoyl-phosphatidylethanolamine (DOPE), 1, 2-distearoyl-glycero-3- phosphoethanolamine (DSPE), 1, 2-Dioleoyl- phosphatidylcholine (DOPC), 1 - Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1, 2-Dioleoyl-sn-glycero-3- phosphoserine (DOPS), 1, 2- Dipalmitoylphosphatidyl
- DOPA 2- Di
- sterols are a subgroup of steroids consisting of steroid alcohols, and are known to those in the art.
- examples of sterols include cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, and derivatives thereof such as cholestanol, tocopherol, cholestanone, cholestenone, coprostanol, cholesteryl-2'- hydroxyethyl ether, cholesteryl-4'- hydroxybutyl ether, and mixtures thereof.
- immune response refers to the development of a humoral (antibody mediated), cellular (mediated by antigen-specific T cells or their secretion products) or both humoral and cellular response directed against a protein, peptide, carbohydrate, or polypeptide of the disclosure in a recipient patient.
- a humoral antibody mediated
- cellular mediated by antigen-specific T cells or their secretion products
- humoral and cellular response directed against a protein, peptide, carbohydrate, or polypeptide of the disclosure in a recipient patient.
- Such a response can be an active response induced by administration of immunogen or a passive response induced by administration of antibody, antibody containing material, or primed T-cells.
- a cellular immune response is elicited by the presentation of polypeptide epitopes in association with Class I or Class II MHC molecules, to activate antigen-specific CD4 (+) T helper cells and/or CD8 (+) cytotoxic T cells.
- the response may also involve activation of monocytes, macrophages, NK cells, basophils, dendritic cells, astrocytes, microglia cells, eosinophils or other components of innate immunity.
- active immunity refers to any immunity conferred upon a subject by administration of an antigen.
- passive immunity refers to any immunity conferred upon a subject without administration of an antigen to the subject.
- LNP compositions described herein can be used to encapsulate nucleic acids (such as RNA).
- encapsulating agents such as a lipid
- LNP lipid nanoparticle
- a lipid may be a naturally occurring lipid or a synthetic lipid. However, a lipid is usually a biological substance.
- Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glucolipids, sulphatides, lipids with ether and ester- linked fatty acids and polymerizable lipids, and combinations thereof.
- a lipid is a substance that is insoluble in water and extractable with an organic solvent. Compounds other than those specifically described herein are understood by one of skill in the art as lipids, and are encompassed by the compositions and methods of the present disclosure.
- a lipid component and a non-lipid may be attached to one another, either covalently or non-covalently.
- LNPs can be designed to protect RNAs (e.g., saRNA, mRNA) from extracellular RNases and/or can be engineered for systemic delivery of the RNA to target cells.
- RNAs e.g., saRNA, mRNA
- such LNPs may be particularly useful to deliver RNAs when RNAs are intravenously administered to a subject in need thereof.
- such LNPs may be particularly useful to deliver RNAs when RNAs are intramuscularly administered to a subject in need thereof.
- the LNPs described herein can further be administered via intravenous, intramuscular, subcutaneous, intratumoral, intranasal, or inhalation routes of administration.
- a lipid nanoparticle or LNP refers to particles of any morphology generated when a cationic lipid and optionally one or more further lipids are combined, e.g. in an aqueous environment and/or in the presence of RNA.
- lipid nanoparticles are included in a formulation that can be used to deliver an active agent or therapeutic agent, such as a nucleic acid (e.g., mRNA) to a target site of interest (e.g., cell, tissue, organ, tumor, and the like).
- the lipid nanoparticles of the present disclosure comprise a nucleic acid, a polymer-lipid conjugate, a cationic lipid, and at least one structural lipid.
- Such lipid nanoparticles can further comprise one or more additional excipients, e.g., one or more neutral lipids, charged lipids, steroids, or combinations thereof.
- the active agent or therapeutic agent such as a nucleic acid (e.g., mRNA)
- a nucleic acid e.g., mRNA
- the nucleic acid (e.g., mRNA) or a portion thereof may also be associated and complexed with the lipid nanoparticle.
- a lipid nanoparticle may comprise any lipid capable of forming a particle to which the nucleic acids are attached, or in which the one or more nucleic acids are encapsulated.
- the lipid nanoparticles may have an average particle size (as measured by their mean diameter) of about 1 to 500 nm, or about 20 to 500 nm.
- the lipid nanoparticles have a mean diameter of from about 20 nm to about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or at least, at most, exactly, or between any two of 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 n
- mean diameter refers to the mean hydrodynamic diameter of particles as measured by dynamic laser light scattering (DLS) with data analysis using the so-called cumulant algorithm, which provides as results the so-called Z-average with the dimension of a length, and the polydispersity index (PI), which is dimensionless (Koppel, D., J. Chem. Phys.57, 1972, pp 4814-4820, ISO 13321).
- PI polydispersity index
- “mean diameter,” “diameter,” or “size” for particles is used synonymously with this value of the Z-average.
- LNPs described herein may exhibit a polydispersity index less than about 0.5, less than about 0.4, less than about 0.3, or about 0.2 or less.
- the LNPs can exhibit a polydispersity index of at least, at most, exactly, or between any two of 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, or 0.5.
- the polydispersity index is, in some aspects, calculated based on dynamic light scattering measurements by the so-called cumulant analysis as mentioned in the definition of the "average diameter.” Under certain prerequisites, it can be taken as a measure of the size distribution of an ensemble of nanoparticles.
- nucleic acids e.g., RNAs
- LNPs are liver-targeting lipid nanoparticles.
- the RNA solution and lipid preparation mixture or compositions thereof may have, have at least, have at most, have exactly, or have between any two of about 1%, about 2%, about 3%, about 4% about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 56%, about
- LNPs described herein can be prepared using a wide range of methods that may involve obtaining a colloid from at least one cationic or cationically ionizable lipid or lipid-like material and/or at least one cationic polymer and mixing the colloid with nucleic acid to obtain nucleic acid particles.
- the term "colloid” as used herein relates to a type of homogeneous mixture in which dispersed particles do not settle out. The insoluble particles in the mixture are microscopic, with particle sizes between 1 and 1000 nm. The mixture may be termed a colloid or a colloidal suspension. Sometimes the term "colloid" only refers to the particles in the mixture and not the entire suspension.
- colloids comprising at least one cationic or cationically ionizable lipid or lipid-like material and/or at least one cationic polymer
- methods are applicable herein that are conventionally used for preparing liposomal vesicles and are appropriately adapted.
- the most commonly used methods for preparing liposomal vesicles share the following fundamental stages: (i) lipids dissolution in organic solvents, (ii) drying of the resultant solution, and (iii) hydration of dried lipid (using various aqueous media).
- film hydration method lipids are firstly dissolved in a suitable organic solvent, and dried down to yield a thin film at the bottom of the flask.
- the obtained lipid film is hydrated using an appropriate aqueous medium to produce a liposomal dispersion. Furthermore, an additional downsizing step may be included.
- Reverse phase evaporation is an alternative method to the film hydration for preparing liposomal vesicles that involves formation of a water-in-oil emulsion between an aqueous phase and an organic phase containing lipids. A brief sonication of this mixture is required for system homogenization. The removal of the organic phase under reduced pressure yields a milky gel that turns subsequently into a liposomal suspension.
- ethanol injection technique refers to a process, in which an ethanol solution comprising lipids is rapidly injected into an aqueous solution through a needle.
- the RNA lipoplex particles described herein are obtainable by adding RNA to a colloidal liposome dispersion.
- colloidal liposome dispersion is, in some embodiments, formed as follows: an ethanol solution comprising lipids, such as cationic lipids and additional lipids, is injected into an aqueous solution under stirring.
- the RNA lipoplex particles described herein are obtainable without a step of extrusion.
- extruding refers to the creation of particles having a fixed, cross-sectional profile. In particular, it refers to the downsizing of a particle, whereby the particle is forced through filters with defined pores.
- Other methods having organic solvent free characteristics may also be used according to the present disclosure for preparing a colloid.
- LNP-encapsulated RNA can be produced by rapid mixing of an RNA solution described herein (e.g., the RNA product solution) and a lipid preparation described herein (comprising, e.g., at least one cationic lipid and optionally one or more other lipid components, in an organic solvent) under conditions such that a sudden change in solubility of lipid component(s) is triggered, which drives the lipids towards self-assembly in the form of LNPs.
- suitable buffering agents comprise tris, histidine, citrate, acetate, phosphate, or succinate.
- the pH of a liquid formulation relates to the pKa of the encapsulating agent (e.g. cationic lipid).
- the pH of the acidifying buffer may be at least half a pH scale less than the pKa of the encapsulating agent (e.g. cationic lipid), and the pH of the final buffer may be at least half a pH scale greater than the pKa of the encapsulating agent (e.g. cationic lipid).
- properties of a cationic lipid are chosen such that nascent formation of particles occurs by association with an oppositely charged backbone of a nucleic acid (e.g., RNA). In this way, particles are formed around the nucleic acid, which, for example, in some aspects, can result in much higher encapsulation efficiency than is achieved in the absence of interactions between nucleic acids and at least one of the lipid components.
- nucleic acids when present in the lipid nanoparticles, are resistant in aqueous solution to degradation with a nuclease.
- Lipid nanoparticles comprising nucleic acids and their method of preparation are disclosed in, e.g., U.S. Patent Publication Nos. 2004/0142025, 2007/0042031 and PCT Pub. Nos. WO 2013/016058 and WO 2013/086373, the full disclosures of which are herein incorporated by reference in their entirety for all purposes.
- Some embodiments described herein relate to compositions, methods and uses involving more than one, e.g., 2, 3, 4, 5, 6 or even more nucleic acid species such as RNA species.
- each nucleic acid species is separately formulated as an individual LNP formulation.
- each individual LNP formulation will comprise one nucleic acid species.
- the individual LNP formulations may be present as separate entities, e.g. in separate containers.
- Such formulations are obtainable by providing each nucleic acid species separately (typically each in the form of a nucleic acid-containing solution) together with suitable cationic or cationically ionizable lipids or lipid-like materials and cationic polymers that allow the formation of LNPs.
- Respective particles will contain exclusively the specific nucleic acid species that is being provided when the particles are formed (individual particulate formulations).
- a composition such as a pharmaceutical composition comprises more than one individual LNP formulation.
- Respective pharmaceutical compositions can be referred to as mixed LNP formulations.
- Mixed LNP formulations according to the invention can be obtained by forming, separately, individual LNP formulations, as described above, followed by a step of mixing of the individual LNP formulations. By the step of mixing, a formulation comprising a mixed population of nucleic acid-containing LNPs is obtainable. Individual LNP populations may be together in one container, comprising a mixed population of individual LNP formulations. Alternatively, it is possible that different nucleic acid species are formulated together as a combined LNP formulation.
- Such formulations are obtainable by providing a combined formulation (typically combined solution) of different RNA species together with suitable cationic or cationically ionizable lipids or lipid-like materials and cationic polymers that allow the formation of LNPs.
- a combined LNP formulation will typically comprise LNPs that comprise more than one RNA species.
- different RNA species are typically present together in a single particle.
- Polymeric Materials Given their high degree of chemical flexibility, polymeric materials are commonly used for nanoparticle-based delivery. Accordingly, those skilled in the art will be familiar with the types of polymers that can be used in polymer-lipid conjugates as described herein.
- cationic materials are used to electrostatically condense the negatively charged nucleic acid into nanoparticles.
- These positively charged groups often consist of amines that change their state of protonation in the pH range between 5.5 and 7.5, thought to lead to an ion imbalance that results in endosomal rupture.
- Polymers such as poly-L-lysine, polyamidoamine, protamine and polyethyleneimine, as well as naturally occurring polymers such as chitosan have all been applied to nucleic acid delivery and are suitable as cationic materials useful in some embodiments herein.
- some investigators have synthesized polymeric materials specifically for nucleic acid delivery.
- synthetic materials may be suitable for use as cationic materials herein.
- a "polymeric material,” as used herein, is given its ordinary meaning, i.e., a molecular structure comprising one or more repeat units (monomers), connected by covalent bonds.
- repeat units can all be identical; alternatively, in some cases, there can be more than one type of repeat unit present within the polymeric material.
- a polymeric material is biologically derived, e.g., a biopolymer such as a protein.
- additional moieties can also be present in the polymeric material, for example targeting moieties such as those described herein.
- a polymer (or polymeric moiety) utilized in accordance with the present disclosure may be a copolymer. Repeat units forming the copolymer can be arranged in any fashion.
- repeat units can be arranged in a random order; alternatively or additionally, in some embodiments, repeat units may be arranged in an alternating order, or as a "block" copolymer, i.e., comprising one or more regions each comprising a first repeat unit (e.g., a first block), and one or more regions each comprising a second repeat unit (e.g., a second block), etc.
- Block copolymers can have two (a diblock copolymer), three (a triblock copolymer), or more numbers of distinct blocks.
- a polymeric material for use in accordance with the present disclosure is biocompatible. Biocompatible materials are those that typically do not result in significant cell death at moderate concentrations.
- a biocompatible material is biodegradable, i.e., is able to degrade, chemically and/or biologically, within a physiological environment, such as within the body.
- a polymeric material may be or comprise protamine or polyalkyleneimine, in particular protamine.
- protamine is often used to refer to any of various strongly basic proteins of relatively low molecular weight that are rich in arginine and are found associated especially with DNA in place of somatic histones in the sperm cells of various animals (as fish).
- a polyalkyleneimine comprises polyethylenimine and/or polypropylenimine.
- the polyalkyleneimine is polyethyleneimine (PEI).
- the polyalkyleneimine is a linear polyalkyleneimine, e.g., linear polyethyleneimine (PEI).
- Cationic materials contemplated for use herein include those which are able to electrostatically bind nucleic acid.
- cationic polymeric materials contemplated for use herein include any cationic polymeric materials with which nucleic acid can be associated, e.g. by forming complexes with the nucleic acid or forming vesicles in which the nucleic acid is enclosed or encapsulated.
- particles described herein may comprise polymers other than cationic polymers, e.g., non-cationic polymeric materials and/or anionic polymeric materials. Collectively, anionic and neutral polymeric materials are referred to herein as non-cationic polymeric materials.
- lipids and lipid-like materials may be cationic, anionic or neutral.
- Neutral lipids or lipid-like materials exist in an uncharged or neutral zwitterionic form at a selected pH.
- lipids may be divided into eight categories: fatty acids and their derivatives (including tri-, di-, monoglycerides, and phospholipids), glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, polyketides, sterol lipids as well as sterol-containing metabolites such as cholesterol, and prenol lipids.
- fatty acids include, but are not limited to, fatty esters and fatty amides.
- glycerolipids include, but are not limited to, glycosylglycerols and glycerophospholipids (e.g., phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine).
- sphingolipids include, but are not limited to, ceramides phosphosphingolipids (e.g., sphingomyelins, phosphocholine), and glycosphingolipids (e.g., cerebrosides, gangliosides).
- sterol lipids include, but are not limited to, cholesterol and its derivatives and tocopherol and its derivatives.
- Use of structural lipids in the lipid nanoparticle may help mitigate aggregation of other lipids in the particle, and can influence the LNP morphology.
- Structural lipids include, but are not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha- tocopherol, hopanoids, phytosterols, steroids, and mixtures thereof.
- the structural lipid is a sterol.
- sterols are a subgroup of steroids consisting of steroid alcohols.
- the structural lipid is a steroid.
- the structural lipid is cholesterol.
- the structural lipid is an analog of cholesterol.
- the structural lipid is alpha-tocopherol.
- the structural lipid can be a monoacylglycerol (such as glyceryl monoolein (GMO)).
- the structural lipid can be an aliphatic alcohol (such as phytantriol (PHY)). It will be appreciated that more than one such structural lipids can be used, and the present disclosure includes any combination of such structural lipids.
- lipid-like material lipid-like compound
- lipid-like molecule relates to substances that structurally and/or functionally relate to lipids but may not be considered as lipids in a strict sense.
- the term includes compounds that are able to form amphiphilic layers as they are present in vesicles, multilamellar/unilamellar liposomes, or membranes in an aqueous environment and includes surfactants, or synthesized compounds with both hydrophilic and hydrophobic moieties.
- the term refers to molecules, which comprise hydrophilic and hydrophobic moieties with different structural organization, which may or may not be similar to that of lipids.
- the RNA solution and lipid preparation mixture or compositions thereof may comprise cationic lipids, neutral lipids, cholesterol, and/or polymer-lipid conjugates (e.g., polyethylene glycol conjugated to a lipid) which form lipid nanoparticles that encompass the RNA molecules.
- the LNP may comprise a cationic lipid and one or more excipients, e.g., one or more neutral lipids, charged lipids, steroids or steroid analogs (e.g., cholesterol), polymer- lipid conjugates (e.g. PEG-lipid), or combinations thereof.
- the LNPs encompass, or encapsulate, the nucleic acid molecules.
- encapsulate As used herein, “encapsulate,” “encapsulated,” “encapsulation,” and grammatically comparable variants thereof mean that at least a portion of a substance is enclosed or surrounded by another material or another substance in a composition.
- a substance such as a nucleic acid
- Cationic Lipids Cationic or cationically ionizable lipids or lipid-like materials refer to a lipid or lipid-like material capable of being positively charged and able to electrostatically bind nucleic acid.
- a "cationic lipid” or “cationic lipid-like material” refers to a lipid or lipid like material having a net positive charge. Cationic lipids or lipid-like materials bind negatively charged nucleic acid by electrostatic interaction. Generally, cationic lipids possess a lipophilic moiety, such as a sterol, an acyl chain, a diacyl or more acyl chains, and the head group of the lipid typically carries the positive charge. Exemplary cationic lipids include one or more amine group(s) which bear the positive charge. Cationic lipids may encapsulate negatively charged RNA.
- cationic lipids are ionizable such that they can exist in a positively charged or neutral form depending on pH.
- the ionization of the cationic lipid affects the surface charge of the lipid nanoparticle under different pH conditions. Without wishing to be bound by theory, this ionizable behavior is thought to enhance efficacy through helping with endosomal escape and reducing toxicity as compared with particles that remain cationic at physiological pH.
- such "cationically ionizable" lipids or lipid-like materials are comprised by the term "cationic lipid” or “cationic lipid-like material” unless contradicted by the circumstances.
- a cationic lipid may comprise from about 0.05 mol% to about 100 mol%, about 0.1 mol% to about 100 mol%, about 1 mol% to about 100 mol%, about 10 mol % to about 100 mol %, about 20 mol % to about 100 mol %, about 30 mol % to about 100 mol %, about 40 mol % to about 100 mol %, or about 50 mol % to about 100 mol % of the total lipid present in the particle.
- a cationic lipid may be at least, at most, exactly, or between any two of 0.05 mol%, 0.1 mol%, 1 mol%, 10 mol %, 20 mol %, 30 mol %, 40 mol %, 50 mol %, 60 mol %, 70 mol %, 80 mol %, 90 mol %, or 100 mol %, or any range or value derivable therein, of the total lipid present in the particle.
- the amount of the cationic lipid can also be selected taking the amount of the nucleic acid cargo into account.
- these amounts are selected such as to result in an N/P ratio of the nanoparticle(s) or of the composition in the range from at least, at most, exactly, or between any two of about 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or any range or value derivable therein.
- lipid formulations are formed at N/P ratios larger than four and up to twelve, because positively charged nanoparticles are considered favorable for transfection. In that case, RNA is considered to be completely bound to nanoparticles.
- the N/P ratio is defined as the mole ratio of the nitrogen atoms (“N”) of the basic nitrogen-containing groups of the lipid to the phosphate groups (“P”) of the nucleic acid which is used as cargo.
- the N/P ratio where a charge equilibrium exists, depends on the pH.
- the N/P ratio may be calculated on the basis that, for example, 1 ⁇ g RNA typically contains about 3 nmol phosphate residues, provided that the RNA exhibits a statistical distribution of bases.
- the “N”-value of the lipid may be calculated on the basis of its molecular weight and the relative content of permanently cationic and—if present— cationizable groups.
- the lipid nanoparticles of the present disclosure comprise one or more cationic lipids.
- cationic lipids include, but are not limited to: ((4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); 1,2-dioleoyl-3- trimethylammonium propane (DOTAP); N,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 3-(N — (N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), dimethyldioctadecylammonium (DDAB); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-diacyloxy-3-dimethylammonium propanes; 1,2-dialkyloxy-3- dimethylammonium propanes; di
- Additional cationic lipids contemplated to be within the present disclosure include those disclosed in, e.g., U.S. 10,166,298, and US 2020-0206362A1, the full disclosures of which are herein incorporated by reference in their entirety for all purposes.
- Additional Lipids in certain aspects, can comprise one or more additional lipids or lipid-like materials that stabilize the formation of particles during their formation. Suitable stabilizing lipids include non-cationic lipids, e.g., neutral lipids and anionic lipids, which include the structural lipids as described herein.
- an "anionic lipid” refers to any lipid that is negatively charged at a selected pH.
- neutral lipid refers to any one of a number of lipid species that exist in either an uncharged or neutral zwitterionic form at physiological pH.
- additional lipids comprise one of the following neutral lipid components: (1) a phospholipid, (2) cholesterol or a derivative thereof; or (3) a mixture of a phospholipid and cholesterol or a derivative thereof.
- Representative neutral lipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidic acids, phosphatidylserines, ceramides, sphingomyelins, dihydro-sphingomyelins, cephalins, and cerebrosides.
- Exemplary phospholipids include, for example, phosphatidylcholines, e.g., diacylphosphatidylcholines, such as distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC), palmitoyloleoy
- the neutral lipid is 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC).
- the LNPs comprise a neutral lipid, and the neutral lipid comprises one or more of DSPC, DPPC, DMPC, DOPC, POPC, DOPE, or SM.
- the LNPs further comprise a steroid or steroid analogue.
- a “steroid” is a compound comprising the following carbon skeleton: .
- the steroid or steroid analogue is cholesterol.
- the LNPs comprise a polymer-lipid conjugate.
- An example of a polymer-lipid conjugate is a pegylated lipid. Pegylated lipids are known in the art and are further described herein.
- the polyethylene glycol-lipid is PEG-2000-DMG.
- the polyethylene glycol-lipid is PEG-c-DOMG).
- the polyethylene glycol-lipid is 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (PEG-DMA).
- the LNPs comprise a PEGylated diacylglycerol (PEG-DAG) such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG), a PEGylated phosphatidylethanoloamine (PEG-PE), a PEG succinate diacylglycerol (PEG-S-DAG) such as 4-O-(2′,3′-di(tetradecanoyloxy)propyl-1-O-((o- methoxy(polyethoxy)ethyl)butanedioate (PEG-S-DMG), a PEGylated ceramide (PEG- cer), or a PEG dialkoxypropylcarbamate such as co-
- PEG-lipids are disclosed in, e.g., U.S. 9,737,619, the full disclosure of which is herein incorporated by reference in its entirety for all purposes.
- the molar ratio of the cationic lipid to the pegylated lipid ranges from about 100:1 to about 20:1, e.g., from about 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, or 100:1, or any range or value derivable therein.
- the PEG lipid is present in the LNP in an amount from about 0.1 to about 10 mole percent (mol %) (e.g., at least, at most, exactly, or between any two of 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mol %), relative to the total lipid content of the nanoparticle. In one aspect, the PEG lipid is present in the LNP in an amount from about 1 to about 5 mole percent. In one aspect, the PEG lipid is present in the LNP in about 1 mole percent or about 1.5 mole percent.
- the relative amount of lipids in the LNPs of the present disclosure may affect important nucleic acid particle characteristics, such as charge, particle size, stability, tissue selectivity, and bioactivity of the nucleic acid. Accordingly, the relative amounts of lipids within the LNPs of the present disclosure are described herein.
- Prolonged Immune Response from Vaccinations The slow cellular internalization of GMO:Chol LNPs poses benefits for sustained antigen production during vaccination with mRNA-LNPs, which is emerging to be useful for improve immunogenicity. A slow delivery has recently been shown useful for difficult vaccination targets for example, HIV (J.H. Lee et al. Nature 609, pp. 998–1004 (2022).
- LNPs for Controlled Release LNPs that have a sustained, or controlled, release profile can be used for a variety of therapeutic and prophylactic purposes, such as for cancer and/or immunotherapy.
- therapeutic areas that may benefit would involve a local administration (e.g. intradermal, intramuscular, intratumoral etc.) See, e.g., Ziller et al. Mol. Pharmaceutics 15, 2, pp. 642–651 (2016).
- Some therapeutic areas in which controlled/sustained release of mRNA could be applied include but are not limited to: local cancers that require intratumoral injection e.g. pancreatic cancer (localized not unresectable) (Narayanan et al., J.
- the LNPs of the present disclosure may allow sustained or delayed release of the polynucleotide, primary construct, or mRNA (eg, after intramuscular or subcutaneous injection).
- the altered release profile for the polynucleotide, the primary construct, or the mRNA may result, for example, in the translation of an encoded protein over an extended period of time.
- the LNPs of the present disclosure can also be used to increase the stability of the polynucleotide, primary construct, or mRNA.
- Biodegradable polymers have previously been used to protect nucleic acids other than mRNA from degradation and have been shown to produce sustained release of payloads in vivo (Rozema et al., Proc Natl Acad Sci USA. 2007104:12982- 12887; Sullivan et al., Expert Opin Drug Deliv. 20107:1433- 1446.
- the pharmaceutical compositions of the present disclosure may be sustained release formulations. Sustained release formulations may be for subcutaneous administration. Accordingly, the present disclosure provides LNPs that have a delayed release profile of the RNA contained therein.
- an LNP provides a release profile that is 0.001% or less, 0.005% or less, 0.01% or less, 0.05% or less, 0.1% or less, 0.5% or less, 1% or less, 5% or less, 10% or less, 20% or less, 30% or less, 40% or less, 50% or less, 60% or less, 70% or less, 80% or less, 90% or less, or 95% or less, of the release profile of a comparator LNP that does not have a delayed release profile.
- comparator LNPs can be any of those disclosed in WO 2013/086373 and WO 2021/213924, or the standard LNP control, DSPC:Chol (10:37.5 [denoted as 198]) LNP as described in Example 9 herein.
- DSPC:Chol 10:37.5 [denoted as 198]
- lipidic phase a cationic lipid (Dlin-MC3-DMA), helper lipid (GMO) and PEG-lipid (DMG- or DOPE-PEG) were combined in the ratio of lipid components as shown in Table 1.
- Dlin-MC3-DMA ranged from 1.5-50%
- GMO ranged from 48.5-97%
- PEG lipid was maintained at 1.5%.
- modified mRNA was diluted in citrate buffer, pH 5.5. The aqueous to lipid ratio was 3:1, at a total flow rate of 12 mL/min. After the LNPs were formed, they were dialyzed using 10 mM Tris buffer, pH 7.5 overnight.
- RNA integrity was determined by fragment analyzer, using capillary gel electrophoresis and the value for one of the formulations was 80%.
- the amount of RNA degradation determined from the area of the curve of late migrating species (LMS) and the value of one of the formulations was 6%.
- Example 2 Glyceryl Monoolein and Cholesterol LNP Formulation-Two Helper Lipids
- LNPs were formed via microfluidic mixing of an aqueous and lipidic phase, using a Nanoassemblr device.
- a cationic lipid Dlin-MC3-DMA
- GMO and cholesterol two helper lipids
- DMG- or DOPE- PEG PEG-lipid
- modified mRNA was diluted in citrate buffer, pH 5.5.
- the aqueous to lipid ratio was 3:1, at a total flow rate of 12 mL/min.
- LNPs were dialyzed using 10 mM Tris buffer, pH 7.5 overnight.
- 300 mM sucrose was added to stabilize the LNPs and then they were stored at -80°C.
- Dynamic light scattering was used to determine the particle size which ranged from 74-175 nm with a polydispersity index ranging from 0.09 to 0.21. When the cholesterol content was less than 71.4 mol%, LNPs formed within the desired size range of ⁇ 120 nm.
- RNA integrity was determined by fragment analyzer, using capillary gel electrophoresis and the values ranged from 80-84%.
- the amount of RNA degradation determined from the area of the curve of late migrating species (LMS) and values ranged from 2-7%.
- LMS late migrating species
- Example 3 Phytantriol LNP Formulation - One Helper Lipid LNPs were formed via microfluidic mixing of an aqueous and lipidic phase, using a Nanoassemblr device. A different helper lipid, phytantriol (PHY) was used in the formulations.
- PHY helper lipid, phytantriol
- lipidic phase a cationic lipid (Dlin-MC3-DMA), helper lipid (PHY) and PEG-lipid (DMG- or DOPE-PEG) were combined in the ratio of lipid components as shown in Table 2.
- Dlin-MC3-DMA ranged from 1.5-50 mol%
- PHY ranged from 48.5-97 mol%
- PEG lipid was maintained at 1.5 mol%.
- modified mRNA was diluted in citrate buffer, pH 5.5. The aqueous to lipid ratio was 3:1, at a total flow rate of 12 mL/min. After the LNPs were formed, they were dialyzed using 10 mM Tris buffer, pH 7.5 overnight.
- RNA assay kit Post dialysis, 300 mM sucrose was added to stabilize the LNPs and then they were stored at -80°C. Dynamic light scattering was used to determine the particle size which ranged from 97 nm to greater than 1000 nm with a polydispersity index ranging from 0.03 to 1.0. When the amount of PHY was less than 90 mol%, the particle size of the LNPs was less than 300 nm. The encapsulation efficiency was determined by a RNA assay kit and ranged from 77-98%. RNA integrity was determined by fragment analyzer, using capillary gel electrophoresis and ranged from 52-81%.
- RNA degradation determined from the area of the curve of late migrating species (LMS) and the value for PHY at 70 mol% was 5%, while it increased to 26% when 48.5 mol% PHY was used in the formulations.
- LMS late migrating species
- Example 4 Phytantriol and Glyceryl Monoolein LNP Formulation - Two Helper Lipids LNPs were formed via microfluidic mixing of an aqueous and lipidic phase, using a Nanoassemblr device. Two different helper lipids (glyceryl monoolein and phytantriol) were used in the formulations.
- lipidic phase a cationic lipid (Dlin- MC3-DMA), two helper lipids (GMO and PHY) and PEG-lipid (DMG- or DOPE-PEG) were combined in the ratio of lipid components as shown in Table 2.
- Dlin-MC3-DMA ranged from 1.5-50 mol%
- GMO ranged from 14.4-77 mol%
- PHY ranged from 10-77 mol%
- PEG lipid was maintained at 1.5 mol%.
- modified mRNA was diluted in citrate buffer, pH 5.5. The aqueous to lipid ratio was 3:1, at a total flow rate of 12 mL/min.
- RNA assay kit RNA integrity was determined by fragment analyzer, using capillary gel electrophoresis and the values ranged from 53-78%. The amount of RNA degradation determined from the area of the curve of late migrating species (LMS) and values ranged from 4-29%. Table 2.
- Phytantriol (PHY) and GMO LNPs investigation detailing the type of lipid used, the associated composition ratio in mol% and nitrogen to phosphate (N/P) ratio.
- CQAs critical quality attributes
- the six exemplary LNP formulations (GMO 70 mol%, GMO:Chol 14.4:55.6 mol%, Chol:GMO 20:77 mol%, PHY 70 mol%, GMO:PHY 14.4:55.6 mol% and PHY:GMO 14.4:55.6 mol%) were all prepared at a larger scale (6 g) and aliquoted into 500 ⁇ L tubes. Samples were split across controlled temperature conditions (5°C and 25°C) at ambient humidity, mimicking refrigerator and room temperature, respectively. At designated timepoints of 0, 7, 14 days as well as 1, 2 and 3 months, an individual sample was removed and tested for particle size, polydispersity, RNA encapsulation and RNA integrity.
- Example 6 Morphology of LNPs Cryo-electron microscopy (EM) was used to visualize the morphologies of the lipid nanoparticles.
- EM Cryo-electron microscopy
- Standard DSPC cholesterol (10:38.5 mol%) LNPs had irregular spherical-like structures with occurrences of “blebs” from the particle surfaces (Error! Reference source not found.A). This structural morphology has previously been reported on by Yanez Arteta et al. (PNAS 2018, 115:E3351). Standard DSPC: cholesterol LNPs also had distinctive shell layer on the particles, indicative of a lamellar-type bilayer. In comparison, 70 mol% GMO LNPs population were spherical and densely packed within the core as observed by the darker colored particles in Error! Reference source not found.B.
- GMO cholesterol (14.4:55.6 mol%) LNPs were less dense in color, but had particle populations with well-defined straight edges, similar to hexagonal shapes, as demonstrated by the white box outlines in Error! Reference source not found.C.
- the core of these particles was similar in density to the shell, showing uniformity throughout the particle.
- Increasing the GMO content and decreasing the cholesterol content i.e. cholesterol: GMO 22:77 mol% LNPs resulted in “bleb” formation, with the inability to distinguish between single particle morphologies, as observed in Error! Reference source not found.D.
- PHY 70 mol% LNPs were again different to GMO 70 mol% LNPs, where particles had both cubic-like shapes (red boxes) as well as uniquely defined graph lines within the core (black boxes, Error! Reference source not found.E).
- the density increased with the occurrence of the cubic shaped particles (Error! Reference source not found.F).
- the dense cubic shaped particles observed for PHY:GMO 14.4:55.6 mol% is further indicative of improved thermostability at 5°C and 25°C.
- Example 7 Morphology of LNPs – Small Angle X-ray Scattering
- SAXS Small angle x-ray scattering
- Example 8 Morphology of LNPs – NMR and Cryo-EM
- the one-dimensional proton nuclear magnetic resonance (1D 1H NMR) spectra of different LNPs is displayed in Figure 4, and provides information on the chemical identity of the surface lipids of the LNPs.
- Samples were measured as intact LNPs. Samples were diluted with 0.2M x DPBS, and spiked 10% D2O, 0.05% trisodium phosphate.
- Different excitation sculpting pulse sequences were used to render the 1D 1H NMR spectra including; (1) 1d1H, sequence: zgesgp -H 90 degree pulse and (2) 1d1H, sequence: PGSTE (stebpesgp1s1d) - T2 filter to suppress excipients signal.
- Surface PEG methylene signals are well resolved on the surface of all LNPs. LNPs with PHY 70%mol (#149) and GMO:PHY 14.4:55.6%mol (#150) show very similar surface lipid profiles, likely attributable to the fact that similar amount of PHY are within the formulation.
- LNPs with GMO 70% (#146) and PHY:GMO 14.4:55.6% (#151) also show very similar surface lipid profiles, for the same reason as PHY, and differ in peak positions only by the chemical shifts of GMO compared to PHY.
- LNPs with GMO:Chol 14.4:55.6%mol (#147) distinctly shows surface lipid profiles with significantly lowest peak intensity (Figure 3). It suggests the less mobile surface lipids and likely a more rigid particle.
- Electron microscopy (EM) shows particles that have stripe patterns that may be caused by the combination of GMO and cholesterol. In Figure 4A, the EM also demonstrated that many particles in this sample are slightly cubic in shape (arrow), which corresponds with the SAXS diffractograms.
- RNA-LNP uptake/association quantitative reverse transcription polymerase chain reaction (RT-qPCR) was employed to quantify the amount of mRNA within the cell after 1 h and 4 h of incubation.
- RT-qPCR quantitative reverse transcription polymerase chain reaction
- smFISH single-molecule Fluorescence in situ Hybridization
- mRNA translation a standard immunofluorescence assay was used to determine the total cell count, the amount of HA positive cells and the mean fluorescence intensity, 24 h post incubation with mRNA-LNPs, where the mRNA encoded for the HA- influenza virus protein.
- GMO:Chol (14.4:55.6 [denoted as 207]) LNPs rapidly associated with the cell, where up to approximately 4x10 7 HA copies were quantified within the cell 1h post transfection, as demonstrated in Figure 6. This was equivalent to the standard LNP control, DSPC:Chol (10:37.5 [denoted as 198]) LNP.
Abstract
The present disclosure relates to lipids, lipid nanoparticles and formulations thereof, and to methods involving the lipids and lipid nanoparticles to deliver one or more therapeutics and/or prophylactics to and/or produce polypeptides in mammalian cells or organs.
Description
PC072873A LIPID NANOPARTICLES TECHNICAL FIELD The present disclosure relates to lipids, lipid nanoparticles and formulations thereof, and to methods involving the lipids and lipid nanoparticles to deliver one or more therapeutics and/or prophylactics to and/or produce polypeptides in mammalian cells or organs. BACKGROUND Lipid nanoparticles (LNPs) are effective drug delivery systems for biologically active compounds, such as therapeutic and/or prophylactic nucleic acids, proteins, and peptides, which are otherwise cell impermeable. Drugs based on nucleic acids, which include large nucleic acid molecules such as, e.g., in vitro transcribed messenger RNA (mRNA) as well as smaller polynucleotides that interact with mRNA or a gene, need to be delivered to the proper cellular compartment to be effective. For example, nucleic acids such as mRNA suffer from their physico-chemical properties that render them impermeable to cells. In addition, nucleic acids such as mRNA are rapidly degraded by nucleases present in blood and other fluids or in tissues and have been shown to stimulate strong immune responses in vitro and in vivo. See, e.g., Robbins et al, Oligonucleotides 19:89-102 (2009); International Patent Application Publication Number WO2016/118697; and Pardi et al. J. Control. Release, 217:345- 351 (2015). Lipid nanoparticle formulations have improved nucleic acid delivery in vivo. For example, such formulations have significantly reduced siRNA doses necessary to achieve target knockdown in vivo (see Zimmermann et al., Nature 441: 111-114, 2006). Further, upon intramuscular administration, LNPs have been shown to enable the uptake by host cells and delivery of mRNA inside the cytosol via endocytosis into an endosome, where translation of the gene of interest can subsequently occur (see, e.g. Liang et al., Mol. Ther., 25:2635-2647 (2017)). Typically, such lipid nanoparticle drug delivery systems are multi-component formulations comprising cationic lipids, helper (or structural) lipids, and lipids containing polyethylene glycol (PEG). The positively charged cationic lipids bind to the anionic nucleic acid, while the other components support a stable self-assembly of the lipid nanoparticles. Efforts have been directed toward improving delivery efficacy of lipid nanoparticle formulations. Many such efforts have been aimed toward developing more appropriate cationic
lipids. See, e.g., Akinc et al., Nature Biotechnology 26:561-569 (2008); Love et al., Proc. Natl. Acad. Sci. USA 107:1864-1869, (2010); Baigude et al., Journal of Controlled Release 107:276-287 (2005); U.S. Patent Publication No.2020-0155691; and Semple et al., Nature Biotechnology 28:172-176 (2010). Certain types of non- cationic lipids, sometimes referred to as “helper lipids”, or “structural lipids”, are thought to mediate structural morphologies of LNPs, including non-lamellar structures. LNPs can form into an array of mesophases, including micelles, micellar cubic, hexagonal, bicontinuous cubic, lamellar, inversed bicontinuous cubic, inversed hexagonal, inversed micellar cubic and inversed micelle mesophases (see, e.g. Eygeris et al., Nono Letters 20, 4543 (2020), and Kaasgaard et al., Phys Chem Chem Phys 2006:8(43):4957-75); WO2022/087686; Han et al. Nat Commun 12, 7233 (2021); and Schoenmaker et al. Int. J. of Pharmaceutics 601: 120586 (2021). The structural morphology of LNPs is considered an essential factor in how the encapsulated cargo is packaged and mediates fusion to the host cell where the cargo is ultimately released, and is the subject of ongoing research (e.g. Eygeris et al., Nano Lett.20:6, 4543-4549 (2020); Gomez-Aguado et al., Nanomaterials 10(2):364 (2020)). Glyceryl monoolein is a structural lipid that has been used in forming LNP structures with cubic morphology (see, e.g. H. Kim & C. Leal, ACS Nano 9(10):10214- 10226 (2015)). Phytantriol is an aliphatic alcohol that is known to form cubic phases at physiological temperatures (see, e.g. Barauskas et al., Langmuir 19:9562-9565 (2003); “Final Report on the Safety Assessment of Phytantriol”, Int. J. Toxicol.26 Supp 1:107-114 (2007). Despites these efforts, there remains a need for LNP formulations that provide high potency following administration, that allow for the administration of lower doses of nucleic acids or other cargo, and that have improved temperature stability. SUMMARY Provided herewith are lipid nanoparticles (LNPs) and pharmaceutical compositions comprising the LNPs. The LNPs and pharmaceutical compositions are particularly useful for delivering a nucleic acid to a patient (e.g., a human) or to a cell. LNP formulations useful for the delivery of nucleic acids frequently employ a polymer- lipid conjugate, such as a PEG-lipid conjugate, which serves to help control particle size during LNP manufacture and prevent unwanted aggregation in the vial and in the blood after administration. The PEG-lipid conjugates also help to prevent unwanted
opsonization in the blood. These PEG-lipid conjugates can use a PEG polymer component with a MW of about 2000. These PEG-lipid conjugates can be employed in molar ratios (relative to other lipids in the composition) of about 0.5% to about 10%. In addition, lower molecular weight PEG polymers (500-1,000) could be employed in molar ratios (relative to other lipids in the composition) of about 0.5% to about 10%. Also, higher molecular weight PEG polymers (5,000-20,000) could be employed in molar ratios (relative to other lipids in the composition) of about 0.2% to about 0.5% (see e.g. WO 2020219941). In addition, LNP formulations typically employ an ionizable lipid (such as a cationic lipid), and at least two structural lipids such as cholesterol and a phospholipid, such as distearoylphosphatidylcholine (DSPC). In contrast, lipid nanoparticle formulations described herein can contain at least one structural lipid selected from a monoacylglycerol and an aliphatic alcohol. For example, LNP formulations described herein can contain an ionizable lipid (such as a cationic lipid), a polymer lipid conjugate (such as a PEG-lipid conjugate), and one or two structural lipids (such as cholesterol, glyceryl monoolein, or phytantriol). Accordingly, and as described more fully herein, new formulations have been developed that use various monacylglycerol and alpiphatic alcohol structural lipids such as glyceryl monoolein and phytantriol, to provide unique structural and beneficial properties for the LNPs. For example, as described more fully herein, new LNP formulations have been developed that use either monoolein or phytantriol as the sole structural lipid, or in combination with cholesterol as the other structural lipid. The present disclosure provides lipid nanoparticles that comprise a nucleic acid, a cationic lipid, a polymer-lipid conjugate, such as a polyethylene glycol (PEG)- lipid conjugate, and at least one structural lipid selected from a monoacylglycerol and an aliphatic alcohol, such as glyceryl monoolein and phytantriol. In addition, the LNPs can comprise additional structural lipids such as sterols, phospholipids, and other structural lipids known in the art. The present disclosure further provides methods of using such LNPs to induce an immune response against a pathogen in a subject, such as a mammal (e.g. in a human); and/or to treat or prevent a disease, disorder, or condition in a subject, such as a mammal (e.g. in a human). For example, one aspect of the present disclosure relates to the administration of a therapeutically effective amount of any of the LNPs described herein to a subject in need thereof for the treatment and/or prevention of a disease or disorder associated with coronaviruses, influenza, varicella zoster virus (shingles), respiratory syncytial virus, and other
bacterial, fungal, or viral infections. In a further aspect, the present disclosure relates to methods of inducing an effective immune response against a pathogen such as those noted herein in order to effectively prevent a disease or disorder in a subject caused by said pathogen, comprising administering an effective amount to said subject of any of the LNPs of the present disclosure. The present disclosure further provides LNPs that have a delayed release profile of the RNA contained therein as compared to LNPs that do not not have a delayed release profile. BRIEF DESCRIPTION OF THE FIGURES Figure 1. The critical quality attributes (CQAs) of six LNPs over a time course period of three months at refrigerator (5 ºC) and room temperature (25 ºC), where A depict the encapsulation efficiency, B depict particle size, C show poly-dispersity index (PDI), and D show the RNA integrity. Figure 2. Representative cryo-electron micrographs of four LNPs, including A. standard DSPC: cholesterol (10:28.5 mol%), B. GMO 70 mol%, C. GMO: cholesterol 14.4:55.6 mol%, D. cholesterol: GMO 22:77 mol%, E. PHY 70 mol% and F PHY:GMO 14.4:55.6 mol%. Arrow bar for all images is the same and shown in panel B, E and F, white boxes indicate flat surfaces of LNPs, and black boxes indicate higher internal structure of LNPs. Figure 3. SAXS diffractograms of various mRNA-LNPs Figure 3A: LNPs containing GMO as the structural lipid (with different variations) compared to DSPC:Chol and Figure 3B: LNPs containing PHY as structural lipid (with different variations) compared to DSPC:Chol Figure 4. 1D-NMR spectrum of various mRNA-LNPs. Figure 5. Cyro-electron microscopy (EM) micrographs of: Figure 5A GMO:Chol 14.4:55.6 %mol and Figure 5B. Chol:GMO 22:77 %mol. Figure 6. Absolute HA copy numbers determined by RT-qPCR at increasing amounts of mRNA-LNPs at A.1 h post transfection and B.4 h post transfection for the seven different formulations.
Figure 7. Cellular internalization determined by cytoplasmic distribution at 4 h post transfection with smFISH quantification of Cali/09/HA positive cells (A) and clusters (B). At 24 h post transfection the cytoplasmic distribution is further shown with the smFISH quantification of Cali/09/HA positive cells (C) and clusters (D). Figure 8. Transfection efficiency is demonstrated in: Figure 8A - the percent positive cells expressing the HA antigen at various mRNA-LNP concentrations and formulations; Figure 8B - the corresponding Mean fluorescence intensity (MFI) data from the various mRNA-LNP concentrations and formulations that are depicted as percent positive in Figure 8A; and Figure 8C - the number of cells present across the experiment after transfection with the various mRNA-LNPs concentration and formulation. DETAILED DESCRIPTION Described below are a number of embodiments (E) of the present disclosure. E1. According to a first aspect of the present disclosure, there is provided a lipid nanoparticle (LNP) comprising: (a) at least one nucleic acid; (b) at least one polymer-lipid conjugate in an amount from about 0.05 to about 5 mol% of the total lipid in the particle; (c) at least one cationic lipid in an amount from about 0.1 to about 50 mol% of the total lipid in the particle; and (d) at least one structural lipid selected from a monoacylglycerol and an aliphatic alcohol, wherein each of said at least one structural lipids is present in an amount from about 10 to about 99 mol% of the total lipid in the particle. E2. The LNP of embodiment E1, wherein the at least one polymer-lipid conjugate is a polyethylene glycol (PEG)-lipid conjugate. E3. The LNP of embodiment E2, wherein the PEG-lipid conjugate is present in an amount from about 0.1 to about 10 mol% of the total lipid in the particle. E4. The LNP of embodiment E2, wherein the PEG-lipid conjugate is present in an amount from about 0.5 to about 5 mol% of the total lipid in the particle. E5. The LNP of embodiment E2, wherein the PEG-lipid conjugate is present in an amount from about 1 to about 2 mol% of the total lipid in the particle. E6. The LNP of embodiment E2, wherein the PEG-lipid conjugate is present in an amount of about 1.5 mol% of the total lipid in the particle.
E7. The LNP of embodiment E2, wherein the PEG-lipid conjugate is selected from: dimyristoylphosphatidylcholine-polyethylene glycol-2000 (DMPC-PEG); 1,2- dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG); 1,2-dioleoyl- sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] ammonium salt (DOPE-PEG); 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-poly (ethylene glycol)-2000 (DSPE-PEG); mPEG-N,N-ditetradecylacetamide (ALC-0159); and oleoyl polyethylene glycol 2000. E8. The LNP of embodiment E1, wherein the at least one cationic lipid is present in an amount from about 0.5 to about 40 mol% of the total lipid in the particle. E9. The LNP of embodiment E1, wherein the at least one cationic lipid is present in an amount from about 1 to about 35 mol% of the total lipid in the particle. E10. The LNP of embodiment E1, wherein the at least one cationic lipid is present in an amount from about 5 to about 30 mol% of the total lipid in the particle. E11. The LNP of embodiment E1, wherein the at least one cationic lipid is present in an amount from about 10 to about 20 mol% of the total lipid in the particle. E12. The LNP of embodiment E1, wherein the at least one cationic lipid is selected from: (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4- (dimethylamino)butanoate (Dlin-MC3-DMA); [(4-hydroxybutyl)azanediyl]di(hexane- 6,1-diyl) bis(2-hexyldecanoate) (ALC-0315); 2-[2,2-bis[(9Z,12Z)-octadeca-9,12- dienyl]-1,3-dioxolan-4-yl]-N,N-dimethylethanamine (DLin-KC2-DMA); 1,2- dilinoleyloxy-n,n-dimethyl-3-aminopropane (DLinDMA); N,N-dimethyl-2,3-bis[(Z)- octadec-9-enoxy]propan-1-amine (DODMA); 5- carboxyspermylglycinedioctadecylamide (DOGS); and 1,2-dioleoyl-3- dimethylammonium-propane (DODAP). E13. The LNP of embodiment E12, wherein the at least one cationic lipid is Dlin-MC3-DMA. E14. The LNP of embodiment E1, wherein the at least one structural lipid is glyceryl monoolein (GMO). E15. The LNP of embodiment E14, wherein GMO is present in an amount from about 10 to about 99 mol% of the total lipid in the particle. E16. The LNP of embodiment E14, wherein GMO is present in an amount from about 20 to about 90 mol% of the total lipid in the particle. E17. The LNP of embodiment E14, wherein GMO is present in an amount from about 30 to about 80 mol% of the total lipid in the particle.
E18. The LNP of embodiment E14, wherein GMO is present in an amount from about 40 to about 70 mol% of the total lipid in the particle. E19. The LNP of embodiment E14, wherein GMO is present in an amount from about 50 to about 60 mol% of the total lipid in the particle. E20. The LNP of embodiment E14, wherein GMO is present in an amount from about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90 or about 99 mol% of the total lipid in the particle. E21. The LNP of embodiment E1, wherein the at least one structural is phytantriol (PHY). E22. The LNP of embodiment E21, wherein PHY is present in an amount from about 10 to about 99 mol% of the total lipid in the particle. E23. The LNP of embodiment E21, wherein PHY is present in an amount from about 20 to about 90 mol% of the total lipid in the particle. E24. The LNP of embodiment E21, wherein PHY is present in an amount from about 30 to about 80 mol% of the total lipid in the particle. E25. The LNP of embodiment E21, wherein PHY is present in an amount from about 40 to about 70 mol% of the total lipid in the particle. E26. The LNP of embodiment E21, wherein PHY is present in an amount from about 50 to about 60 mol% of the total lipid in the particle. E27. The LNP of embodiment E21, wherein PHY is present in an amount from about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90 or about 99 mol% of the total lipid in the particle. E28. The LNP of embodiment E1, comprising at least one monoacylglycerol structural lipid and at least one aliphatic alcohol structural lipid. E29. The LNP of embodiment E28, wherein the monoacylglycerol is GMO. E30. The LNP of embodiment E28, wherein the aliphatic alcohol is PHY. E31. The LNP of embodiment E28, wherein the monoacylglycerol is GMO, and the aliphatic alcohol is PHY. E32. The LNP of embodiment E31, wherein GMO and PHY are each present in an amount from about 10 to about 98.5 mol% of the total lipid in the particle. E33. The LNP of embodiment E1, further comprising at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol, wherein said at least one additional structural lipid is present in an amount from about 10 to about 75 mol% of the total lipid present in the particle.
E34. The LNP of embodiment E33, wherein said at least one additional structural lipid is a sterol. E35. The LNP of embodiment E34, wherein said sterol is cholesterol. E36. The LNP of embodiment E33, wherein said at least one additional structural lipid is a phospholipid. E37. The LNP of embodiment E36, wherein said phospholipid is distearoylphosphatidylcholine (DSPC). E38. The LNP of embodiment E35, wherein cholesterol is present in an amount from about 10 to about 75 mol% of the total lipid present in the particle. E39. The LNP of embodiment E37, wherein DSPC is present in an amount from about 10 to about 75 mol% of the total lipid present in the particle. E40. The LNP of embodiment E33, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 14.4 mol%; the at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol is cholesterol and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DOPE- PEG and is present in an amount of about 1.5 mol%. E41. The LNP of embodiment E33, wherein: the at least one cationic lipid is present in an amount of about 1.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 77 mol%; the at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol is cholesterol and is present in an amount of about 20 mol%; and the at least one polymer-lipid conjugate is DOPE- PEG and is present in an amount of about 1.5 mol%. E42. The LNP of embodiment E1, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is PHY and is present in an amount of about 70 mol%; and the at least one polymer-lipid conjugate is DMG-PEG and is present in an amount of about 1.5 mol%. E43. The LNP of embodiment E1, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 14.4 mol%; a second structural lipid is PHY and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DOPE-PEG and is present in an amount of about 1.5 mol%. E44. The LNP of embodiment E1, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is PHY and
is present in an amount of about 14.4 mol%; a second structural lipid is GMO and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DMG-PEG and is present in an amount of about 1.5 mol%. E45. The LNP of embodiment E1, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 70 mol%; and the at least one polymer-lipid conjugate is DOPE-PEG and is present in an amount of about 1.5 mol%. E46. The LNP of any one of embodiments E1-E45, wherein the particle size of the LNP is less than about 500 nm. E47. The LNP of embodiment E46, wherein the particle size of the LNP is from about 20 to about 500 nm. E48. The LNP of embodiment E47, wherein the particle size of the LNP is from about 20 to about 300 nm. E49. The LNP of embodiment E48, wherein the particle size of the LNP is from about 20 to about 200 nm. E50. The LNP of embodiment E49, wherein the particle size of the LNP is from about 20 to about 150 nm. E51. The LNP of embodiment E50, wherein the particle size of the LNP is from about 20 to about 100 nm. E52. The LNP of embodiment E49, wherein the particle size of the LNP is about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, or about 200 nm. E53. A composition comprising the LNPs of any one of embodiments E1-E45, wherein the average particle size of the LNPs is less than about 500 nm. E54. The composition of embodiment E53, wherein the average particle size of the LNPs is from about 20 to about 500 nm. E55. The composition of embodiment E54, wherein the average particle size of the LNPs is from about 20 to about 300 nm. E56. The composition of embodiment E55, wherein the average particle size of the LNPs is from about 20 to about 200 nm. E57. The composition of embodiment E56, wherein the average particle size of the LNPs is from about 20 to about 150 nm.
E58. The composition of embodiment E57, wherein the average particle size of the LNPs is from about 20 to about 100 nm. E59. The composition of embodiment E56, wherein the average particle size of the LNPs is about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, or about 200 nm. E60. The LNP of any one of embodiments E1-E45, wherein the nucleic acid is DNA, plasmid DNA, minicircle DNA, ceDNA (closed ended DNA), siRNA, mRNA, miRNA, self-replicating RNA, CRISPR RNA, a gene editing construct, an RNA editing construct, a base editing construct, or a prime editing construct. E61. The LNP of any one of embodiments E1-E45, wherein the at least one nucleic acid is mRNA. E62. A pharmaceutical composition comprising the LNP of any one of embodiments of E1-E45, and a pharmaceutically acceptable carrier. E63. The pharmaceutical composition of embodiment E62, which is formulated for intravenous, intramuscular, subcutaneous, intratumoral, intranasal, or inhalation administration. E64. A method for delivering a nucleic acid to a cell comprising contacting the cell with the LNP of any one of embodiments E1-E45, or E60-E61. E65. A method for delivering a nucleic acid of interest to a subject comprising administering to the subject at least one dose of the composition of embodiment E62. E66. The method of embodiment E65, wherein the nucleic acid is mRNA that encodes at least one protein of interest. E67. The method of embodiment E66, wherein the at least one protein of interest is a therapeutic protein. E68. The method of embodiment E66, wherein the at least one protein of interest is a vaccine antigen. E69. A method for treating a disease characterized by a genetic defect that results in a deficiency of a functional protein, the method comprising: administering to a subject having the disease, the LNP of embodiment E66, wherein the mRNA encodes the functional protein or a protein having the same biological activity as the functional protein. E70. A method for inducing an immune response against a pathogen in a subject comprising administering to the subject the LNP of embodiment E66, wherein
the mRNA encodes a protein antigen from said pathogen, or an immunogenic variant or fragment thereof. E71. The LNP of any one of embodiments E1-E45, for the therapeutic or prophylactic treatment of a disease characterized by a genetic defect that results in a deficiency of a functional protein. E72. The LNP of any one of embodiments E1-E45, for the therapeutic or prophylactic treatment of a disease characterized by overexpression of a polypeptide. E73. The LNP of any one of embodiments E1-E45, for the prophylactic treatment of a disease caused by a pathogen. Definitions Throughout this application, the term “about” is used according to its plain and ordinary meaning in the area of lipid chemistry and formulations to indicate a deviation of ±10% of the value(s) to which it is attached. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it was individually recited herein. The use of the word “a” or “an” when used in conjunction with the term “comprising” may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The phrase “and/or” means “and” or “or.” To illustrate, A, B, and/or C includes: A alone, B alone, C alone, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C. In other words, “and/or” operates as an inclusive or. The terms “administer”, “administration”, or “administer”, and the like, describe the introduction of the relevant LNP or composition to a subject, such as a mammal (e.g. a human) by a particular route or vehicle. Routes of administration may include, but are not limited to, topical, parenteral and enteral which include oral, buccal, sub- lingual, nasal, anal, gastrointestinal, subcutaneous, intramuscular and intradermal routes of administration. The terms “treat”, “treatment”, or “treating”, and the like, describe the administration of the relevant LNP or composition to a subject, such as a mammal (e.g. a human) to at least ameliorate, reduce or suppress existing signs or symptoms
of a disease, disorder or condition experienced by the subject, to the extent that the medical condition is improved according to clinically acceptable standard(s). For example, “to treat a bacterial infection” means to reduce the infection, or eradicate the infection, or relieve symptoms of the infection in a subject, wherein the improvement and relief are evaluated with a clinically acceptable standardized test and/or an empirical test, including swab sample testing and the like. As used herein, the terms “prevent”, “preventing” or “preventative” mean prophylactically administering the relevant LNP or composition to a subject, such as a mammal (e.g. a human) who does not exhibit signs or symptoms of a disease disorder or condition, but who is expected or anticipated to likely exhibit such signs or symptoms in the absence of prevention. Preventative treatment may at least lessen or partly ameliorate expected symptoms or signs. As used herein, “effective amount” or “therapeutically effective amount” refers to the administration of an amount of the relevant particle or composition sufficient to prevent the occurrence of symptoms of the condition being treated, or to bring about a halt in the worsening of symptoms or to treat and alleviate or at least reduce the severity of the symptoms. The effective amount will vary in a manner which would be understood by a person of skill in the art with patient age, sex, weight etc. An appropriate dosage or dosage regime can be ascertained through routine trial or based on current treatment regimes for the active being delivered via an LNP of the present disclosure. As used herein, the terms "subject" or "individual" or "patient" may refer to any subject, particularly a vertebrate subject, and even more particularly a mammalian subject, for whom therapy is desired. Suitable vertebrate animals include, but are not restricted to, primates, avians, livestock animals (e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and captive wild animals (e.g., foxes, deer, dingoes). A preferred subject is a human in need of treatment for a disease, disorder or condition as described herein. However, it will be understood that the aforementioned terms do not imply that symptoms are necessarily present. A “nucleic acid,” as used herein, is a molecule comprising nucleic acid components and refers to DNA or RNA molecules. It may be used interchangeably with the term "polynucleotide”. A nucleic acid molecule is a polymer comprising or consisting of nucleotide monomers, which are covalently linked to each other by
phosphodiester-bonds of a sugar/phosphate-backbone. Nucleic acids may also encompass modified nucleic acid molecules, such as, for example, base-modified, sugar-modified or backbone-modified DNA or RNA molecules. Nucleic acids can exist in a variety of forms such as: isolated segments and recombinant vectors of incorporated sequences or recombinant polynucleotides encoding polypeptides, such as antigens or one or both chains of an antibody, or a fragment, derivative, mutein, or variant thereof, polynucleotides sufficient for use as hybridization probes, PCR primers or sequencing primers for identifying, analyzing, mutating or amplifying a polynucleotide encoding a polypeptide, anti-sense nucleic acids for inhibiting expression of a polynucleotide, mRNA, saRNA, and complementary sequences of the foregoing described herein. Nucleic acids can be single-stranded or double-stranded and can comprise RNA and/or DNA nucleotides and artificial variants thereof (e.g., peptide nucleic acids). In some cases, a nucleic acid sequence may encode a polypeptide sequence with additional heterologous coding sequences, for example to allow for purification of the polypeptide, transport, secretion, post-translational modification, or for therapeutic benefits such as targeting or efficacy. A tag or other heterologous polypeptide may be added to the modified polypeptide-encoding sequence, wherein “heterologous” refers to a polypeptide that is not the same as the modified polypeptide. The term “polynucleotide” refers to a nucleic acid molecule that can be recombinant or has been isolated from total genomic nucleic acid. Included within the term “polynucleotide” are oligonucleotides (nucleic acids that are 100 residues or less in length), recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like. Polynucleotides include, in certain aspects, regulatory sequences, isolated substantially away from their naturally occurring genes or protein encoding sequences. Polynucleotides may be single-stranded (coding or antisense) or double-stranded, and may be RNA, DNA (genomic, cDNA, or synthetic), analogs thereof, or a combination thereof. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide. In certain aspects, there are polynucleotide variants having substantial identity to the sequences disclosed herein; those comprising equal to any one of, at least any one of, at most any one of, or between any two of 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity, compared to a polynucleotide sequence provided herein using the methods described herein (e.g., BLAST analysis
using standard parameters). In certain aspects, the isolated polynucleotide will comprise a nucleotide sequence encoding a polypeptide that has at least 90% identity to an amino acid sequence described herein, over the entire length of the sequence; or a nucleotide sequence complementary to said isolated polynucleotide. In some aspects, the isolated polynucleotide will comprise a nucleotide sequence encoding a polypeptide that has at least 95% identity to an amino acid sequence described herein, over the entire length of the sequence; or a nucleotide sequence complementary to said isolated polynucleotide. The nucleic acid segments, regardless of the length of the coding sequence itself, may be combined with other nucleic acid sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. The nucleic acids can be any length. They can be, for example, equal to any one of, at least any one of, at most any one of, or between any two of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1500, 3000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000 or more nucleotides in length, and/or can comprise one or more additional sequences, for example, regulatory sequences, and/or be a part of a larger nucleic acid, for example, a vector. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length being limited by the ease of preparation and use in the intended recombinant nucleic acid protocol. In this respect, the term “gene” is used to refer to a nucleic acid that encodes a protein, polypeptide, or peptide (including any sequences required for proper transcription, post-translational modification, or localization). As will be understood by those in the art, this term encompasses genomic sequences, expression cassettes, cDNA sequences, and smaller engineered nucleic acid segments that express, or may be adapted to express, proteins, polypeptides, domains, peptides, fusion proteins, and mutants. A nucleic acid encoding all or part of a polypeptide may contain a contiguous nucleic acid sequence encoding all or a portion of such a polypeptide. It also is contemplated that a particular polypeptide may be encoded by nucleic acids containing variations having slightly different nucleic acid sequences but, nonetheless, encode the same or substantially similar polypeptide. As used herein, the term “expression” of a nucleic acid sequence refers to the generation of any gene product from the nucleic acid sequence. In some
embodiments, a gene product can be a transcript. In some embodiments, a gene product can be a polypeptide. In some embodiments, expression of a nucleic acid sequence involves one or more of the following: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, etc.); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein. In general, the term “engineered” refers to the aspect of having been manipulated by the hand of man. For example, a polynucleotide is considered to be “engineered” when two or more sequences that are not linked together in that order in nature are manipulated by the hand of man to be directly linked to one another in the engineered polynucleotide and/or when a particular residue in a polynucleotide is non- naturally occurring and/or is caused through action of the hand of man to be linked with an entity or moiety with which it is not linked in nature. The term “DNA,” as used herein, means a nucleic acid molecule comprising nucleotides such as deoxy-adenosine-monophosphate, deoxy-thymidine- monophosphate, deoxy-guanosine-monophosphate and deoxy-cytidine- monophosphate monomers which are composed of a sugar moiety (deoxyribose), a base moiety and a phosphate moiety, and polymerize by a characteristic backbone structure. The backbone structure is, typically, formed by phosphodiester bonds between the sugar moiety of the nucleotide, i.e. deoxyribose, of a first and a phosphate moiety of a second, adjacent monomer. The specific order of the monomers, i.e. the order of the bases linked to the sugar/phosphate-backbone, is called the DNA sequence. DNA may be single stranded or double stranded. In the double stranded form, the nucleotides of the first strand typically hybridize with the nucleotides of the second strand, e.g. by A/T-base-pairing and G/C-base-pairing. DNA can contain all, or a majority of, deoxyribonucleotide residues. As used herein, the term “deoxyribonucleotide” means a nucleotide lacking a hydroxyl group at the 2′ position of a β-D-ribofuranosyl group. Without any limitation, DNA can encompass double stranded DNA, antisense DNA, single stranded DNA, isolated DNA, synthetic DNA, DNA that is recombinantly produced, and modified DNA. The term “RNA,” as used herein, means a nucleic acid molecule comprising nucleotides such as adenosine-monophosphate, uridine-monophosphate, guanosine- monophosphate and cytidine-monophosphate monomers which are connected to each other along a so-called backbone. The backbone is formed by phosphodiester
bonds between the sugar, i.e. ribose, of a first and a phosphate moiety of a second, adjacent monomer. RNA may be obtainable by transcription of a DNA-sequence, e.g., inside a cell. In eukaryotic cells, transcription is typically performed inside the nucleus or the mitochondria. In vivo, transcription of DNA may result in premature RNA which is processed into messenger-RNA (mRNA). Processing of the premature RNA, e.g. in eukaryotic organisms, comprises various posttranscriptional modifications such as splicing, 5′ capping, polyadenylation, export from the nucleus or the mitochondria. Mature messenger RNA is processed and provides the nucleotide sequence that may be translated into an amino acid sequence of a peptide or protein. A mature mRNA may comprise a 5′ cap, a 5′ UTR, an open reading frame, a 3′ UTR and a poly-A tail sequence. RNA can contain all, or a majority of, ribonucleotide residues. As used herein, the term “ribonucleotide” means a nucleotide with a hydroxyl group at the 2′ position of a β-D-ribofuranosyl group. In one aspect, RNA can be messenger RNA (mRNA) that relates to a RNA transcript which encodes a peptide or protein. As known to those of skill in the art, mRNA generally contains a 5′ untranslated region (5′ UTR), a polypeptide coding region, and a 3′ untranslated region (3′ UTR). Without any limitation, RNA can encompass double stranded RNA, antisense RNA, single stranded RNA, isolated RNA, synthetic RNA, RNA that is recombinantly produced, and modified RNA (modRNA). An “isolated RNA” is defined as an RNA molecule that can be recombinant or has been isolated from total genomic nucleic acid. An isolated RNA molecule or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell. A “modified RNA” or “modRNA” refers to an RNA molecule having at least one addition, deletion, substitution, and/or alteration of one or more nucleotides as compared to naturally occurring RNA. Such alterations can refer to the addition of non- nucleotide material to internal RNA nucleotides, or to the 5′ and/or 3′ end(s) of RNA. In one aspect, such modRNA contains at least one modified nucleotide, such as an alteration to the base of the nucleotide. For example, a modified nucleotide can replace one or more uridine and/or cytidine nucleotides. For example, these replacements can occur for every instance of uridine and/or cytidine in the RNA sequence, or can occur for only select uridine and/or cytidine nucleotides. Such alterations to the standard nucleotides in RNA can include non-standard nucleotides, such as chemically synthesized nucleotides or deoxynucleotides. For example, at
least one uridine nucleotide can be replaced with 1-methylpseudouridine in an RNA sequence. Other such altered nucleotides are known to those of skill in the art. Such altered RNAs are considered analogs of naturally-occurring RNA. In some aspects, the RNA is produced by in vitro transcription using a DNA template, where DNA refers to a nucleic acid that contains deoxyribonucleotides. In some aspects, the RNA can be replicon RNA (replicon), in particular self-replicating RNA, or self-amplifying RNA (saRNA). As contemplated herein, without any limitations, RNA can be used as a therapeutic modality to treat and/or prevent a number of conditions in mammals, including humans. Methods described herein comprise administration of the RNA described herein to a mammal, such as a human. For example, in one aspect such methods of use for RNA include an antigen-coding RNA vaccine to induce robust neutralizing antibodies and accompanying/concomitant T-cell response to achieve protective immunization. In some aspects, minimal vaccine doses are administered to induce robust neutralizing antibodies and accompanying/concomitant T-cell response to achieve protective immunization. In one aspect, the RNA administered is in vitro transcribed RNA. For example, such RNA can be used to encode at least one antigen intended to generate an immune response in said mammal. Pathogenic antigens are peptide or protein antigens derived from a pathogen associated with infectious disease. The term "antigen" may refer to a substance, which is capable of being recognized by the immune system, e.g., by the adaptive immune system, and which is capable of eliciting an antigen-specific immune response, e.g. by formation of antibodies and/or antigen-specific T cells as part of an adaptive immune response. An antigen may be or may comprise a peptide or protein, which may be presented by the MHC to T-cells. An antigen may be the product of translation of a provided nucleic acid molecule, e.g., an RNA molecule comprising at least one coding sequence as described herein. In addition, fragments, variants and derivatives of an antigen, such as a peptide or a protein, comprising at least one epitope are understood as antigens. As used herein, the term “lipid” refers to a chemical compound that is insoluble in water and extractable with an organic solvent. Lipids may be naturally occurring, or synthetic. Typically, a lipid is a biological compound. Compounds other than those specifically described herein are understood by one of skill in the art as lipids, and are encompassed by the compositions and methods of the present disclosure. A lipid
component and a non-lipid may be attached to one another, either covalently or non- covalently. As used herein, the term “lipid nanoparticle”, or “LNP”, refers to particles of any morphology generated when a cationic lipid and optionally one or more further lipids are combined, e.g. in an aqueous environment and/or in the presence of a nucleic acid such as RNA. In some aspects, lipid nanoparticles are included in a formulation that can be used to deliver an active agent or therapeutic agent, such as a nucleic acid (e.g., mRNA) to a target site of interest (e.g., cell, tissue, organ, tumor, and the like). In some aspects, the lipid nanoparticles of the present disclosure comprise a nucleic acid. Such lipid nanoparticles typically comprise a cationic lipid and one or more excipients, e.g., one or more neutral lipids, charged lipids, steroids, polymer conjugated lipids, or combinations thereof. In some aspects, the active agent or therapeutic agent, such as a nucleic acid (e.g., mRNA), may be encapsulated in the lipid portion of the lipid nanoparticle or an aqueous space enveloped by some or all of the lipid portion of the lipid nanoparticle, thereby protecting it from enzymatic degradation or other undesirable effects induced by the mechanisms of the host organism or cells e.g. an adverse immune response. The nucleic acid (e.g., mRNA) or a portion thereof may also be associated and complexed with the lipid nanoparticle. A lipid nanoparticle may comprise any lipid capable of forming a particle to which the nucleic acids are attached, or in which the one or more nucleic acids are encapsulated. The LNPs disclosed herein typically have a mean diameter of from about 1 nm to about 500 nm. The term "mean diameter" refers to the mean hydrodynamic diameter of particles as measured by dynamic laser light scattering (DLS) with data analysis using the so-called cumulant algorithm, which provides as results the so-called Z-average with the dimension of a length, and the polydispersity index (PI), which is dimensionless (Koppel, D., J. Chem. Phys. 57, 1972, pp 4814-4820, ISO 13321). Here, "mean diameter," "diameter," or "size" for particles is used synonymously with this value of the Z-average. The term “polymer-lipid conjugate” refers to a molecule comprising both a lipid portion and a polymer portion. An example of a polymer-lipid conjugate is a pegylated lipid. The term “pegylated lipid” (PEG lipid) refers to a molecule comprising both a lipid portion and a polyethylene glycol portion. Pegylated lipids are known in the art and include lipids such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-s-DMG), 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, poly-
ethylene glycol conjugated lipids in C14-C18 range, i.e. DMPC-PEG (Dimyristoylphosphatidylcholine-polyethylene glycol-2000), DMG-PEG (1,2- dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000), DOPE-PEG (1,2- dioleoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] ammonium salt), DSPE-PEG (1, 2-Distearoyl-sn-glycero-3-phosphoethanolamine- Poly (ethylene glycol)-2000), ALC-0159, oleoyl polyethylene glycol 2000, and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol), and the like. Other examples of polymer-lipid conjugates include polyoxazolines, poly (2- methyl-2-oxazoline) (PMOZ), poly (2-ethyl-2-oxazoline) (PEOZ), polysarcosines, polyglycerol polymer conjugates (i.e. PG-30), and polycarbonate polymer conjugates (i.e. PCs) and the like. As used herein, a "cationic lipid" refers to a lipid or lipid like material having a net positive charge. Cationic lipids bind negatively charged nucleic acid by electrostatic interaction. Generally, cationic lipids possess a lipophilic moiety, such as a sterol, an acyl chain, a diacyl or more acyl chains, and the head group of the lipid typically carries the positive charge. Exemplary cationic lipids include one or more amine group(s) which bear the positive charge. Cationic lipids may encapsulate negatively charged RNA. In some aspects, cationic lipids are ionizable such that they can exist in a positively charged or neutral form depending on pH. The ionization of the cationic lipid affects the surface charge of the lipid nanoparticle under different pH conditions. Without wishing to be bound by theory, this ionizable behavior is thought to enhance efficacy through helping with endosomal escape and reducing toxicity as compared with particles that remain cationic at physiological pH. For purposes of the present disclosure, such "cationically ionizable" lipids are comprised by the term "cationic lipid” unless contradicted by the circumstances. Without limitation, examples of cationic lipids include Dlin-MC3-DMA ((6Z,9Z,28Z,31Z)-Heptatriaconta-6,9,28,31- tetraen-19-yl 4-(dimethylamino)butanoate), ALC-0315 ([(4- hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2-hexyldecanoate)), DLin-KC2-DMA (2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-N,N- dimethylethanamine), DLinDMA (1,2-dilinoleyloxy-n,n-dimethyl-3-aminopropane), DODMA (N,N-dimethyl-2,3-bis[(Z)-octadec-9-enoxy]propan-1-amine), DOGS (5- carboxyspermylglycinedioctadecylamide), DODAP (1,2-Dioleoyl-3- Dimethylammonium-Propane), DOSPA (2,3-dioleyloxy-N-[2(spermine- carboxamido)ethyl]-N,N-dimethyl-1-propanaminium), DOTAP (1,2-Dioleoyl-3-
Trimethylammonium-Propane), DSDMA (1,2-distearyloxy-N,N-dimethyl-3- aminopropane), DLenDMA (1,2-dilinolenyloxy-N,N-dimethyl-3-aminopropane), DODAC (N-dioleyl-N,N-dimethylammonium chloride), DDAB (N,N-distearyl-N,N- dimethylammonium bromide), DMRIE (N-[1,2-dimyristyloxyprop-3-yl]-N,N-dimethyl-N- hydroxyethyl ammonium bromide), CLinDMA (3-dimethylamino-2-(cholest-5-en-3- beta-oxybutan-4-oxy)-1-(cis,cis-9,12-oc-tadecadienoxy)propane), CpLinDMA (2-[5′- (cholest-5-en-3-beta-oxy)-3′-oxapentoxy)-3-dimethy 1-1-(cis,cis-9′,1-2′- octadecadienoxy)propane), and DMOBA (N,N-dimethyl-3,4-dioleyloxybenzylamine). As used herein, a “structural lipid” is a lipid that helps stabilize the formation of LNPs during their formation, and can mediate the morphology of an LNP. Such structural lipids (sometimes referred to as “helper lipids”) include non-cationic lipids, e.g., neutral lipids and anionic lipids (e.g. phospholipids). Without limitation, examples of structural lipids include monoacyglycerols, aliphatic alcohols, and sterols. Without wishing to be bound by any theory, optimizing the formulation of LNPs by addition of such structural lipids in addition to a cationic lipid, may enhance particle stability and efficacy of nucleic acid delivery. As used herein, the terms “monoacylglycerol” and “aliphatic alcohol” are classes of chemical compounds known to those in the art, and can include, without limitation, monoolein, 2-monoolein, citrem, oleoyl lactate, oleamide, monoelaidin, linoleic acid, monomyristolein, elaidic acid, glyceryl monoolein (GMO), monopalmitolein, monolinolein, monovaccenin, monoerucin, phytantriol (PHY), diolein, triolein, dioleoyl-glycerol, didodecyldimethylammonium bromide, dioctadecyl (dimethyl) ammonium chloride (DOAC/DODMAC) and dimethyldioctadecylammonium bromide (DODAB). As used herein, the term “phospholipid” is any lipid that comprises a phosphate group. Phospholipids are a subset of non-cationic lipids. Without limitation, examples of phospholipids include 1, 2- Dioleoyl-phosphatidic acid (DOPA), 1, 2-Dioleoyl- phosphatidylglycerol (DOPG), 1, 2- Distearoyl-phophatidylglycerol (DSPG), 1, 2- Dioleoyl-phosphatidylethanolamine (DOPE), 1, 2-distearoyl-glycero-3- phosphoethanolamine (DSPE), 1, 2-Dioleoyl- phosphatidylcholine (DOPC), 1 - Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1, 2-Dioleoyl-sn-glycero-3- phosphoserine (DOPS), 1, 2- Dipalmitoylphosphatidylserine (DPPS), lyso1 -hydroxy- 2-oleoyl-sn-glycero-3- phosphocholine, 1, 2-dioleoyl-sn-glycero-3- dihexyl- phosphocholine, and distearoylphosphatidylcholine (DSPC).
As used herein, sterols are a subgroup of steroids consisting of steroid alcohols, and are known to those in the art. Without limitation, examples of sterols include cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, and derivatives thereof such as cholestanol, tocopherol, cholestanone, cholestenone, coprostanol, cholesteryl-2'- hydroxyethyl ether, cholesteryl-4'- hydroxybutyl ether, and mixtures thereof. As used herein the phrase “immune response” or its equivalent “immunological response” refers to the development of a humoral (antibody mediated), cellular (mediated by antigen-specific T cells or their secretion products) or both humoral and cellular response directed against a protein, peptide, carbohydrate, or polypeptide of the disclosure in a recipient patient. Such a response can be an active response induced by administration of immunogen or a passive response induced by administration of antibody, antibody containing material, or primed T-cells. A cellular immune response is elicited by the presentation of polypeptide epitopes in association with Class I or Class II MHC molecules, to activate antigen-specific CD4 (+) T helper cells and/or CD8 (+) cytotoxic T cells. The response may also involve activation of monocytes, macrophages, NK cells, basophils, dendritic cells, astrocytes, microglia cells, eosinophils or other components of innate immunity. As used herein “active immunity” refers to any immunity conferred upon a subject by administration of an antigen. As used herein “passive immunity” refers to any immunity conferred upon a subject without administration of an antigen to the subject. Nucleic Acid Encapsulation The LNP compositions described herein can be used to encapsulate nucleic acids (such as RNA). In one aspect, encapsulating agents (such as a lipid), which can be used to produce a lipid nanoparticle (LNP)-encapsulated RNA. Without intending to be bound by any theory, it is believed that the cationic or cationically ionizable lipid or lipid-like material and/or the cationic polymer combine together with the nucleic acid to form aggregates, and this aggregation results in colloidally stable particles. A lipid may be a naturally occurring lipid or a synthetic lipid. However, a lipid is usually a biological substance. Biological lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glucolipids, sulphatides, lipids with ether and ester- linked fatty acids and polymerizable lipids, and combinations thereof. A lipid is a
substance that is insoluble in water and extractable with an organic solvent. Compounds other than those specifically described herein are understood by one of skill in the art as lipids, and are encompassed by the compositions and methods of the present disclosure. A lipid component and a non-lipid may be attached to one another, either covalently or non-covalently. In some aspects, LNPs can be designed to protect RNAs (e.g., saRNA, mRNA) from extracellular RNases and/or can be engineered for systemic delivery of the RNA to target cells. In some aspects, such LNPs may be particularly useful to deliver RNAs when RNAs are intravenously administered to a subject in need thereof. In some aspects, such LNPs may be particularly useful to deliver RNAs when RNAs are intramuscularly administered to a subject in need thereof. Accordingly, the LNPs described herein can further be administered via intravenous, intramuscular, subcutaneous, intratumoral, intranasal, or inhalation routes of administration. A lipid nanoparticle or LNP refers to particles of any morphology generated when a cationic lipid and optionally one or more further lipids are combined, e.g. in an aqueous environment and/or in the presence of RNA. In some aspects, lipid nanoparticles are included in a formulation that can be used to deliver an active agent or therapeutic agent, such as a nucleic acid (e.g., mRNA) to a target site of interest (e.g., cell, tissue, organ, tumor, and the like). In some aspects, the lipid nanoparticles of the present disclosure comprise a nucleic acid, a polymer-lipid conjugate, a cationic lipid, and at least one structural lipid. Such lipid nanoparticles can further comprise one or more additional excipients, e.g., one or more neutral lipids, charged lipids, steroids, or combinations thereof. In some aspects, the active agent or therapeutic agent, such as a nucleic acid (e.g., mRNA), may be encapsulated in the lipid portion of the lipid nanoparticle or an aqueous space enveloped by some or all of the lipid portion of the lipid nanoparticle, thereby protecting it from enzymatic degradation or other undesirable effects induced by the mechanisms of the host organism or cells e.g. an adverse immune response. The nucleic acid (e.g., mRNA) or a portion thereof may also be associated and complexed with the lipid nanoparticle. A lipid nanoparticle may comprise any lipid capable of forming a particle to which the nucleic acids are attached, or in which the one or more nucleic acids are encapsulated. In some aspects, the lipid nanoparticles may have an average particle size (as measured by their mean diameter) of about 1 to 500 nm, or about 20 to 500 nm. In some aspects, the lipid nanoparticles have a mean diameter of from about 20 nm to
about 150 nm, from about 40 nm to about 150 nm, from about 50 nm to about 150 nm, from about 60 nm to about 130 nm, from about 70 nm to about 110 nm, from about 70 nm to about 100 nm, from about 80 nm to about 100 nm, from about 90 nm to about 100 nm, from about 70 to about 90 nm, from about 80 nm to about 90 nm, from about 70 nm to about 80 nm, or at least, at most, exactly, or between any two of 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm, and are substantially non-toxic. The term "mean diameter" refers to the mean hydrodynamic diameter of particles as measured by dynamic laser light scattering (DLS) with data analysis using the so-called cumulant algorithm, which provides as results the so-called Z-average with the dimension of a length, and the polydispersity index (PI), which is dimensionless (Koppel, D., J. Chem. Phys.57, 1972, pp 4814-4820, ISO 13321). Here, "mean diameter," "diameter," or "size" for particles is used synonymously with this value of the Z-average. LNPs described herein may exhibit a polydispersity index less than about 0.5, less than about 0.4, less than about 0.3, or about 0.2 or less. By way of example, the LNPs can exhibit a polydispersity index of at least, at most, exactly, or between any two of 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0.49, or 0.5. The polydispersity index is, in some aspects, calculated based on dynamic light scattering measurements by the so-called cumulant analysis as mentioned in the definition of the "average diameter." Under certain prerequisites, it can be taken as a measure of the size distribution of an ensemble of nanoparticles. In certain aspects, nucleic acids (e.g., RNAs), when present in provided LNPs, are resistant in aqueous solution to degradation with a nuclease. In some aspects, LNPs are liver-targeting lipid nanoparticles. In certain aspects, the RNA solution and lipid preparation mixture or compositions thereof may have, have at least, have at most, have exactly, or have between any two of about 1%, about 2%, about 3%, about 4% about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about
35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% of a particular lipid, lipid type, or non-lipid component such as lipid- like materials and/or cationic polymers or an adjuvant, antigen, peptide, polypeptide, sugar, nucleic acid or other material disclosed herein or as would be known to one of skill in the art. LNPs described herein can be prepared using a wide range of methods that may involve obtaining a colloid from at least one cationic or cationically ionizable lipid or lipid-like material and/or at least one cationic polymer and mixing the colloid with nucleic acid to obtain nucleic acid particles. The term "colloid" as used herein relates to a type of homogeneous mixture in which dispersed particles do not settle out. The insoluble particles in the mixture are microscopic, with particle sizes between 1 and 1000 nm. The mixture may be termed a colloid or a colloidal suspension. Sometimes the term "colloid" only refers to the particles in the mixture and not the entire suspension. For the preparation of colloids comprising at least one cationic or cationically ionizable lipid or lipid-like material and/or at least one cationic polymer, methods are applicable herein that are conventionally used for preparing liposomal vesicles and are appropriately adapted. The most commonly used methods for preparing liposomal vesicles share the following fundamental stages: (i) lipids dissolution in organic solvents, (ii) drying of the resultant solution, and (iii) hydration of dried lipid (using various aqueous media). In the film hydration method, lipids are firstly dissolved in a suitable organic solvent, and dried down to yield a thin film at the bottom of the flask. The obtained lipid film is hydrated using an appropriate aqueous medium to produce a liposomal dispersion. Furthermore, an additional downsizing step may be included. Reverse phase evaporation is an alternative method to the film hydration for preparing liposomal vesicles that involves formation of a water-in-oil emulsion between
an aqueous phase and an organic phase containing lipids. A brief sonication of this mixture is required for system homogenization. The removal of the organic phase under reduced pressure yields a milky gel that turns subsequently into a liposomal suspension. The term "ethanol injection technique" refers to a process, in which an ethanol solution comprising lipids is rapidly injected into an aqueous solution through a needle. This action disperses the lipids throughout the solution and promotes lipid structure formation, for example lipid vesicle formation such as liposome formation. Generally, the RNA lipoplex particles described herein are obtainable by adding RNA to a colloidal liposome dispersion. Using the ethanol injection technique, such colloidal liposome dispersion is, in some embodiments, formed as follows: an ethanol solution comprising lipids, such as cationic lipids and additional lipids, is injected into an aqueous solution under stirring. In some embodiments, the RNA lipoplex particles described herein are obtainable without a step of extrusion. The term "extruding" or "extrusion" refers to the creation of particles having a fixed, cross-sectional profile. In particular, it refers to the downsizing of a particle, whereby the particle is forced through filters with defined pores. Other methods having organic solvent free characteristics may also be used according to the present disclosure for preparing a colloid. In some aspects, LNP-encapsulated RNA can be produced by rapid mixing of an RNA solution described herein (e.g., the RNA product solution) and a lipid preparation described herein (comprising, e.g., at least one cationic lipid and optionally one or more other lipid components, in an organic solvent) under conditions such that a sudden change in solubility of lipid component(s) is triggered, which drives the lipids towards self-assembly in the form of LNPs. In some aspects, suitable buffering agents comprise tris, histidine, citrate, acetate, phosphate, or succinate. The pH of a liquid formulation relates to the pKa of the encapsulating agent (e.g. cationic lipid). The pH of the acidifying buffer may be at least half a pH scale less than the pKa of the encapsulating agent (e.g. cationic lipid), and the pH of the final buffer may be at least half a pH scale greater than the pKa of the encapsulating agent (e.g. cationic lipid). In some aspects, properties of a cationic lipid are chosen such that nascent formation of particles occurs by association with an oppositely charged backbone of a nucleic acid (e.g., RNA). In this way, particles are formed around the nucleic acid, which, for example, in some aspects, can result in much higher encapsulation efficiency than is
achieved in the absence of interactions between nucleic acids and at least one of the lipid components. In certain aspects, nucleic acids, when present in the lipid nanoparticles, are resistant in aqueous solution to degradation with a nuclease. Lipid nanoparticles comprising nucleic acids and their method of preparation are disclosed in, e.g., U.S. Patent Publication Nos. 2004/0142025, 2007/0042031 and PCT Pub. Nos. WO 2013/016058 and WO 2013/086373, the full disclosures of which are herein incorporated by reference in their entirety for all purposes. Some embodiments described herein relate to compositions, methods and uses involving more than one, e.g., 2, 3, 4, 5, 6 or even more nucleic acid species such as RNA species. In an LNP formulation, it is possible that each nucleic acid species is separately formulated as an individual LNP formulation. In that case, each individual LNP formulation will comprise one nucleic acid species. The individual LNP formulations may be present as separate entities, e.g. in separate containers. Such formulations are obtainable by providing each nucleic acid species separately (typically each in the form of a nucleic acid-containing solution) together with suitable cationic or cationically ionizable lipids or lipid-like materials and cationic polymers that allow the formation of LNPs. Respective particles will contain exclusively the specific nucleic acid species that is being provided when the particles are formed (individual particulate formulations). In some embodiments, a composition such as a pharmaceutical composition comprises more than one individual LNP formulation. Respective pharmaceutical compositions can be referred to as mixed LNP formulations. Mixed LNP formulations according to the invention can be obtained by forming, separately, individual LNP formulations, as described above, followed by a step of mixing of the individual LNP formulations. By the step of mixing, a formulation comprising a mixed population of nucleic acid-containing LNPs is obtainable. Individual LNP populations may be together in one container, comprising a mixed population of individual LNP formulations. Alternatively, it is possible that different nucleic acid species are formulated together as a combined LNP formulation. Such formulations are obtainable by providing a combined formulation (typically combined solution) of different RNA species together with suitable cationic or cationically ionizable lipids or lipid-like materials and cationic polymers that allow the formation of LNPs. As opposed to a
mixed LNP formulation, a combined LNP formulation will typically comprise LNPs that comprise more than one RNA species. In a combined LNP composition, different RNA species are typically present together in a single particle. Polymeric Materials Given their high degree of chemical flexibility, polymeric materials are commonly used for nanoparticle-based delivery. Accordingly, those skilled in the art will be familiar with the types of polymers that can be used in polymer-lipid conjugates as described herein. Typically, cationic materials are used to electrostatically condense the negatively charged nucleic acid into nanoparticles. These positively charged groups often consist of amines that change their state of protonation in the pH range between 5.5 and 7.5, thought to lead to an ion imbalance that results in endosomal rupture. Polymers such as poly-L-lysine, polyamidoamine, protamine and polyethyleneimine, as well as naturally occurring polymers such as chitosan have all been applied to nucleic acid delivery and are suitable as cationic materials useful in some embodiments herein. In addition, some investigators have synthesized polymeric materials specifically for nucleic acid delivery. Poly(P-amino esters), in particular, have gained widespread use in nucleic acid delivery owing to their ease of synthesis and biodegradability. In some embodiments, such synthetic materials may be suitable for use as cationic materials herein. A "polymeric material,” as used herein, is given its ordinary meaning, i.e., a molecular structure comprising one or more repeat units (monomers), connected by covalent bonds. In some embodiments, such repeat units can all be identical; alternatively, in some cases, there can be more than one type of repeat unit present within the polymeric material. In some cases, a polymeric material is biologically derived, e.g., a biopolymer such as a protein. In some cases, additional moieties can also be present in the polymeric material, for example targeting moieties such as those described herein. Those skilled in the art are aware that, when more than one type of repeat unit is present within a polymer (or polymeric moiety), then the polymer (or polymeric moiety) is said to be a "copolymer." In some embodiments, a polymer (or polymeric moiety) utilized in accordance with the present disclosure may be a copolymer. Repeat units forming the copolymer can be arranged in any fashion. For example, in some embodiments, repeat units can be arranged in a random order; alternatively or
additionally, in some embodiments, repeat units may be arranged in an alternating order, or as a "block" copolymer, i.e., comprising one or more regions each comprising a first repeat unit (e.g., a first block), and one or more regions each comprising a second repeat unit (e.g., a second block), etc. Block copolymers can have two (a diblock copolymer), three (a triblock copolymer), or more numbers of distinct blocks. In certain embodiments, a polymeric material for use in accordance with the present disclosure is biocompatible. Biocompatible materials are those that typically do not result in significant cell death at moderate concentrations. In certain embodiments, a biocompatible material is biodegradable, i.e., is able to degrade, chemically and/or biologically, within a physiological environment, such as within the body. In certain embodiments, a polymeric material may be or comprise protamine or polyalkyleneimine, in particular protamine. As those skilled in the art are aware term "protamine" is often used to refer to any of various strongly basic proteins of relatively low molecular weight that are rich in arginine and are found associated especially with DNA in place of somatic histones in the sperm cells of various animals (as fish). In particular, the term "protamine" is often used to refer to proteins found in fish sperm that are strongly basic, are soluble in water, are not coagulated by heat, and yield chiefly arginine upon hydrolysis. In purified form, they are used in a long-acting formulation of insulin and to neutralize the anticoagulant effects of heparin. In some embodiments, a polyalkyleneimine comprises polyethylenimine and/or polypropylenimine. In some embodiments, the polyalkyleneimine is polyethyleneimine (PEI). In some embodiments, the polyalkyleneimine is a linear polyalkyleneimine, e.g., linear polyethyleneimine (PEI). Cationic materials (e.g., polymeric materials, including polycationic polymers) contemplated for use herein include those which are able to electrostatically bind nucleic acid. In some embodiments, cationic polymeric materials contemplated for use herein include any cationic polymeric materials with which nucleic acid can be associated, e.g. by forming complexes with the nucleic acid or forming vesicles in which the nucleic acid is enclosed or encapsulated. In some embodiments, particles described herein may comprise polymers other than cationic polymers, e.g., non-cationic polymeric materials and/or anionic polymeric materials. Collectively, anionic and neutral polymeric materials are referred to herein as non-cationic polymeric materials.
Lipids & Lipid-Like Materials According to the present disclosure, lipids and lipid-like materials may be cationic, anionic or neutral. Neutral lipids or lipid-like materials exist in an uncharged or neutral zwitterionic form at a selected pH. Generally, lipids may be divided into eight categories: fatty acids and their derivatives (including tri-, di-, monoglycerides, and phospholipids), glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, polyketides, sterol lipids as well as sterol-containing metabolites such as cholesterol, and prenol lipids. Examples of fatty acids include, but are not limited to, fatty esters and fatty amides. Examples of glycerolipids include, but are not limited to, glycosylglycerols and glycerophospholipids (e.g., phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine). Examples of sphingolipids include, but are not limited to, ceramides phosphosphingolipids (e.g., sphingomyelins, phosphocholine), and glycosphingolipids (e.g., cerebrosides, gangliosides). Examples of sterol lipids include, but are not limited to, cholesterol and its derivatives and tocopherol and its derivatives. Use of structural lipids in the lipid nanoparticle may help mitigate aggregation of other lipids in the particle, and can influence the LNP morphology. Structural lipids include, but are not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha- tocopherol, hopanoids, phytosterols, steroids, and mixtures thereof. In some embodiments, the structural lipid is a sterol. As defined herein, “sterols” are a subgroup of steroids consisting of steroid alcohols. In certain embodiments, the structural lipid is a steroid. In certain embodiments, the structural lipid is cholesterol. In certain embodiments, the structural lipid is an analog of cholesterol. In certain embodiments, the structural lipid is alpha-tocopherol. In certain embodiments, the structural lipid can be a monoacylglycerol (such as glyceryl monoolein (GMO)). In other embodiments, the structural lipid can be an aliphatic alcohol (such as phytantriol (PHY)). It will be appreciated that more than one such structural lipids can be used, and the present disclosure includes any combination of such structural lipids. The term "lipid-like material," "lipid-like compound," or "lipid-like molecule" relates to substances that structurally and/or functionally relate to lipids but may not be considered as lipids in a strict sense. For example, the term includes compounds that are able to form amphiphilic layers as they are present in vesicles,
multilamellar/unilamellar liposomes, or membranes in an aqueous environment and includes surfactants, or synthesized compounds with both hydrophilic and hydrophobic moieties. Generally speaking, the term refers to molecules, which comprise hydrophilic and hydrophobic moieties with different structural organization, which may or may not be similar to that of lipids. In some aspects, the RNA solution and lipid preparation mixture or compositions thereof may comprise cationic lipids, neutral lipids, cholesterol, and/or polymer-lipid conjugates (e.g., polyethylene glycol conjugated to a lipid) which form lipid nanoparticles that encompass the RNA molecules. Therefore, in some aspects, the LNP may comprise a cationic lipid and one or more excipients, e.g., one or more neutral lipids, charged lipids, steroids or steroid analogs (e.g., cholesterol), polymer- lipid conjugates (e.g. PEG-lipid), or combinations thereof. In some aspects, the LNPs encompass, or encapsulate, the nucleic acid molecules. As used herein, “encapsulate,” “encapsulated,” “encapsulation,” and grammatically comparable variants thereof mean that at least a portion of a substance is enclosed or surrounded by another material or another substance in a composition. In some aspects, a substance, such as a nucleic acid, can be fully enclosed or surrounded by another material or another substance in a composition, such as a lipid. Cationic Lipids Cationic or cationically ionizable lipids or lipid-like materials refer to a lipid or lipid-like material capable of being positively charged and able to electrostatically bind nucleic acid. As used herein, a "cationic lipid" or "cationic lipid-like material" refers to a lipid or lipid like material having a net positive charge. Cationic lipids or lipid-like materials bind negatively charged nucleic acid by electrostatic interaction. Generally, cationic lipids possess a lipophilic moiety, such as a sterol, an acyl chain, a diacyl or more acyl chains, and the head group of the lipid typically carries the positive charge. Exemplary cationic lipids include one or more amine group(s) which bear the positive charge. Cationic lipids may encapsulate negatively charged RNA. In some aspects, cationic lipids are ionizable such that they can exist in a positively charged or neutral form depending on pH. The ionization of the cationic lipid affects the surface charge of the lipid nanoparticle under different pH conditions. Without wishing to be bound by theory, this ionizable behavior is thought to enhance efficacy through helping with endosomal escape and reducing toxicity as compared
with particles that remain cationic at physiological pH. For purposes of the present disclosure, such "cationically ionizable" lipids or lipid-like materials are comprised by the term "cationic lipid” or “cationic lipid-like material" unless contradicted by the circumstances. In some embodiments, a cationic lipid may comprise from about 0.05 mol% to about 100 mol%, about 0.1 mol% to about 100 mol%, about 1 mol% to about 100 mol%, about 10 mol % to about 100 mol %, about 20 mol % to about 100 mol %, about 30 mol % to about 100 mol %, about 40 mol % to about 100 mol %, or about 50 mol % to about 100 mol % of the total lipid present in the particle. In some embodiments, a cationic lipid may be at least, at most, exactly, or between any two of 0.05 mol%, 0.1 mol%, 1 mol%, 10 mol %, 20 mol %, 30 mol %, 40 mol %, 50 mol %, 60 mol %, 70 mol %, 80 mol %, 90 mol %, or 100 mol %, or any range or value derivable therein, of the total lipid present in the particle. The amount of the cationic lipid can also be selected taking the amount of the nucleic acid cargo into account. In one aspect, these amounts are selected such as to result in an N/P ratio of the nanoparticle(s) or of the composition in the range from at least, at most, exactly, or between any two of about 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or any range or value derivable therein. In some aspects, lipid formulations are formed at N/P ratios larger than four and up to twelve, because positively charged nanoparticles are considered favorable for transfection. In that case, RNA is considered to be completely bound to nanoparticles. The N/P ratio is defined as the mole ratio of the nitrogen atoms (“N”) of the basic nitrogen-containing groups of the lipid to the phosphate groups (“P”) of the nucleic acid which is used as cargo. It is correlated to the charge ratio, as the nitrogen atoms (depending on the pH) are usually positively charged and the phosphate groups are negatively charged. The N/P ratio, where a charge equilibrium exists, depends on the pH. The N/P ratio may be calculated on the basis that, for example, 1 μg RNA typically contains about 3 nmol phosphate residues, provided that the RNA exhibits a statistical distribution of bases. The “N”-value of the lipid may be calculated on the basis of its molecular weight and the relative content of permanently cationic and—if present— cationizable groups. In some aspects, the lipid nanoparticles of the present disclosure comprise one or more cationic lipids. Examples of cationic lipids include, but are not limited to: ((4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); 1,2-dioleoyl-3-
trimethylammonium propane (DOTAP); N,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 3-(N — (N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), dimethyldioctadecylammonium (DDAB); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-diacyloxy-3-dimethylammonium propanes; 1,2-dialkyloxy-3- dimethylammonium propanes; dioctadecyldimethyl ammonium chloride (DODAC), 1,2-distearyloxy-N,N-dimethyl-3-aminopropane (DSDMA), 2,3-di(tetradecoxy)propyl- (2-hydroxyethyl)-dimethylazanium (DMRIE), 1,2-dimyristoyl-sn-glycero-3- ethylphosphocholine (DMEPC), 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP), 1,2-dioleyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DORIE), and 2,3-dioleoyloxy-N-[2(spermine carboxamide)ethyl]-N,N-dimethyl-l- propanamium trifluoroacetate (DOSPA), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), dioctadecylamidoglycyl spermine (DOGS), 3-dimethylamino-2-(cholest-5-en-3-beta- oxybutan-4-oxy)-l-(cis,cis-9,12-oc-tadecadienoxy)propane (CLinDMA), 2-[5′-(cholest- 5-en-3-beta-oxy)-3′-oxapentoxy)-3-dimethyl-l-(cis,cis-9',12′- octadecadienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), 1,2-N,N'-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP), 2,3- Dilinoleoyloxy-N,N-dimethylpropylamine (DLinDAP), 1,2-N,N'-Dilinoleylcarbamyl-3- dimethylaminopropane (DLincarbDAP), 1,2-Dilinoleoylcarbamyl-3- dimethylaminopropane (DLinCDAP), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]- dioxolane (DLin-K-DMA), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3] -dioxolane (DLin- K-XTC2-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3] -dioxolane (DLin-KC2- DMA), heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate (DLin- MC3 -DM A) , N-(2-Hydroxyethyl)-N,N-dimethyl-2,3 -bis(tetradecyloxy )-1- propanaminium bromide (DMRIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9- tetradecenyloxy)-1-propanaminium bromide (GAP-DMORIE), (±)-N-(3-aminopropyl)- N,N-dimethyl-2,3-bis(dodecyloxy)-1 -propanaminium bromide (GAP-DLRIE), (±)-N-(3- aminopropyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-l-propanaminium bromide (GAP- DMRIE), N-(2-Aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide (bAE-DMRIE), N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan- 1-aminium (DOBAQ), 2-({8-[(3b)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3- [(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA), 1,2- dimyristoyl-3-dimethylammonium-propane (DMDAP), 1,2-dipalmitoyl-3-
dimethylammonium-propane (DPDAP), N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3- amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide (MVL5), 1,2- dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 2,3-bis(dodecyloxy)-N-(2- hydroxyethyl)-N,N-dimethylpropan-1-amonium bromide (DLRIE), N-(2-aminoethyl)- N,N-dimethyl-2,3-bis(tetradecyloxy)propan-1-aminium bromide (DMORIE), di((Z)- non-2-en-l-yl) 8,8'-((((2(dimethylamino)ethyl)thio)carbonyl)azanediyl)dioctanoate (ATX), N,N-dimethyl-2,3-bis(dodecyloxy)propan-1-amine (DLDMA), N,N-dimethyl- 2,3-bis(tetradecyloxy)propan-1-amine (DMDMA), Di((Z)-non-2-en-l-yl)-9-((4- (dimethylaminobutanoyl)oxy)heptadecanedioate (L319), N-Dodecyl-3-((2- dodecylcarbamoyl-ethyl)-{2-[(2-dodecylcarbamoyl-ethyl)-2-{(2-dodecylcarbamoyl- ethyl)-[2-(2-dodecylcarbamoyl-ethylamino)-ethyl]-amino}-ethylamino)propionamide (lipidoid 98N12-5), 1-[2-[bis(2-hydroxydodecyl)amino]ethyl-[2-[4-[2-[bis(2 hydroxydodecyl)amino]ethyl]piperazin-l-yl]ethyl]amino]dodecan-2-ol (lipidoid 02-200); (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); or heptadecan- 9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy)hexyl) amino) octanoate (SM-102). Additional cationic lipids contemplated to be within the present disclosure include those disclosed in, e.g., U.S. 10,166,298, and US 2020-0206362A1, the full disclosures of which are herein incorporated by reference in their entirety for all purposes. Additional Lipids In certain aspects, the LNPs of the present disclosure can comprise one or more additional lipids or lipid-like materials that stabilize the formation of particles during their formation. Suitable stabilizing lipids include non-cationic lipids, e.g., neutral lipids and anionic lipids, which include the structural lipids as described herein. Without wishing to be bound by theory, optimizing the formulation of LNPs by addition of other hydrophobic moieties, such as cholesterol and lipids, in addition to an ionizable/cationic lipid or lipid-like material may enhance particle stability and efficacy of nucleic acid delivery. As used herein, an "anionic lipid" refers to any lipid that is negatively charged at a selected pH. The term “neutral lipid” refers to any one of a number of lipid species that exist in either an uncharged or neutral zwitterionic form at physiological pH. In some embodiments, additional lipids comprise one of the following neutral lipid
components: (1) a phospholipid, (2) cholesterol or a derivative thereof; or (3) a mixture of a phospholipid and cholesterol or a derivative thereof. Representative neutral lipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phosphatidic acids, phosphatidylserines, ceramides, sphingomyelins, dihydro-sphingomyelins, cephalins, and cerebrosides. Exemplary phospholipids include, for example, phosphatidylcholines, e.g., diacylphosphatidylcholines, such as distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3- phosphocholine (18:0 Diether PC), l-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3- phosphocholine (OChemsPC), and 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC); and phosphatidylethanolamines, e.g., diacylphosphatidylethanolamines, such as dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl- phosphatidylethanolamine (POPE) and dioleoyl-phosphatidylethanolamine 4-(N- maleimidomethyl)-cyclohexane-lcarboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), dilauroyl- phosphatidylethanolamine (DLPE), distearoyl-phosphatidylethanolamine (DSPE), iphytanoyl-phosphatidylethanolamine (DPyPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearioyl-2-oleoylphosphatidyethanol amine (SOPE), and 1,2- dielaidoyl-sn-glycero-3-phophoethanolamine (transDOPE). In one aspect, the neutral lipid is 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC). In some aspects, the LNPs comprise a neutral lipid, and the neutral lipid comprises one or more of DSPC, DPPC, DMPC, DOPC, POPC, DOPE, or SM. In various aspects, the LNPs further comprise a steroid or steroid analogue. A “steroid” is a compound comprising the following carbon skeleton:
. In certain aspects, the steroid or steroid analogue is cholesterol. Examples of cholesterol derivatives include, but are not limited to, cholestanol, cholestanone, cholestenone, coprostanol, cholesteryl-2′-hydroxyethyl ether, cholesteryl-4'- hydroxybutyl ether, tocopherol and derivatives thereof, and mixtures thereof. As discussed herein, in some aspects of the present disclosure the LNPs comprise a polymer-lipid conjugate. An example of a polymer-lipid conjugate is a pegylated lipid. Pegylated lipids are known in the art and are further described herein. In one aspect, the polyethylene glycol-lipid is PEG-2000-DMG. In one aspect, the polyethylene glycol-lipid is PEG-c-DOMG). In another aspect, the polyethylene glycol-lipid is 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (PEG-DMA). In other aspects, the LNPs comprise a PEGylated diacylglycerol (PEG-DAG) such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG), a PEGylated phosphatidylethanoloamine (PEG-PE), a PEG succinate diacylglycerol (PEG-S-DAG) such as 4-O-(2′,3′-di(tetradecanoyloxy)propyl-1-O-((o- methoxy(polyethoxy)ethyl)butanedioate (PEG-S-DMG), a PEGylated ceramide (PEG- cer), or a PEG dialkoxypropylcarbamate such as co-methoxy(polyethoxy)ethyl-N- (2,3di(tetradecanoxy)propyl)carbamate or 2,3-di(tetradecanoxy)propyl-N-(u>- methoxy(polyethoxy)ethyl)carbamate. PEG-lipids are disclosed in, e.g., U.S. 9,737,619, the full disclosure of which is herein incorporated by reference in its entirety for all purposes. In various aspects, the molar ratio of the cationic lipid to the pegylated lipid ranges from about 100:1 to about 20:1, e.g., from about 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, or 100:1, or any range or value derivable therein. In certain aspects, the PEG lipid is present in the LNP in an amount from about 0.1 to about 10 mole percent (mol %) (e.g., at least, at most, exactly, or between any two of 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mol %), relative to the total lipid content of the nanoparticle. In one aspect, the PEG lipid is present in the LNP in an amount from
about 1 to about 5 mole percent. In one aspect, the PEG lipid is present in the LNP in about 1 mole percent or about 1.5 mole percent. Without wishing to be bound by any particular theory, the relative amount of lipids in the LNPs of the present disclosure may affect important nucleic acid particle characteristics, such as charge, particle size, stability, tissue selectivity, and bioactivity of the nucleic acid. Accordingly, the relative amounts of lipids within the LNPs of the present disclosure are described herein. Prolonged Immune Response from Vaccinations The slow cellular internalization of GMO:Chol LNPs poses benefits for sustained antigen production during vaccination with mRNA-LNPs, which is emerging to be useful for improve immunogenicity. A slow delivery has recently been shown useful for difficult vaccination targets for example, HIV (J.H. Lee et al. Nature 609, pp. 998–1004 (2022). Current vaccination strategies enable immunogenic responses to develop against specific viruses that last for hours to days. Humans have naturally evolved to develop longer lasting immune responses against natural infections, some of which can last for weeks. This is of particular importance in cancer vaccination where the immune system requires a prolonged priming response to boost naturally occurring tumor antigens (Grunwitz & Kranz, mRNA Cancer Vaccines – Messages that Prevail; Current Topics in Microbiology and Immunology, SpringerLink Vol. 405 (2017)). Improving vaccinations to induce longer lasting immune responses is of critical importance. Sustained delivery of antigens or sustained production of antigens via slow internalization of mRNA could improve adaptive immune responses of vaccinations (Ou et al., Adv. Drug Del. Rev.187, 11401 (2022)). LNPs for Controlled Release LNPs that have a sustained, or controlled, release profile can be used for a variety of therapeutic and prophylactic purposes, such as for cancer and/or immunotherapy. For example, for applications involving the sustained release of mRNA, therapeutic areas that may benefit would involve a local administration (e.g. intradermal, intramuscular, intratumoral etc.) See, e.g., Ziller et al. Mol. Pharmaceutics 15, 2, pp. 642–651 (2018). Some therapeutic areas in which controlled/sustained release of mRNA could be applied include but are not limited to: local cancers that require intratumoral injection e.g. pancreatic cancer (localized not unresectable) (Narayanan et al., J. Immunother Cancer 2023
11:e006133. doi: 10.1136/jitc-2022-006133), and skin cancers etc. Sustained releasing mRNA-LNP combined with delivery of a cytokine via intratumoral injection could be beneficial towards cancer immunotherapy (Liu et al., J. Controlled Release Vol 345 pp.306-313 (2022)). Accordingly, the LNPs of the present disclosure may allow sustained or delayed release of the polynucleotide, primary construct, or mRNA (eg, after intramuscular or subcutaneous injection). The altered release profile for the polynucleotide, the primary construct, or the mRNA may result, for example, in the translation of an encoded protein over an extended period of time. The LNPs of the present disclosure can also be used to increase the stability of the polynucleotide, primary construct, or mRNA. Biodegradable polymers have previously been used to protect nucleic acids other than mRNA from degradation and have been shown to produce sustained release of payloads in vivo (Rozema et al., Proc Natl Acad Sci USA. 2007104:12982- 12887; Sullivan et al., Expert Opin Drug Deliv. 20107:1433- 1446. The pharmaceutical compositions of the present disclosure may be sustained release formulations. Sustained release formulations may be for subcutaneous administration. Accordingly, the present disclosure provides LNPs that have a delayed release profile of the RNA contained therein. For example, in one aspect, an LNP provides a release profile that is 0.001% or less, 0.005% or less, 0.01% or less, 0.05% or less, 0.1% or less, 0.5% or less, 1% or less, 5% or less, 10% or less, 20% or less, 30% or less, 40% or less, 50% or less, 60% or less, 70% or less, 80% or less, 90% or less, or 95% or less, of the release profile of a comparator LNP that does not have a delayed release profile. For example, such comparator LNPs can be any of those disclosed in WO 2013/086373 and WO 2021/213924, or the standard LNP control, DSPC:Chol (10:37.5 [denoted as 198]) LNP as described in Example 9 herein. EXAMPLES The present disclosure is described in greater detail by way of specific examples. The following examples are offered for illustrative purposes and are not intended to limit the disclosure in any manner. Example 1: Glyceryl Monoolein LNP Formulation- One Helper Lipid
LNPs were formed via microfluidic mixing of an aqueous and lipidic phase, using a Nanoassemblr device. For the lipidic phase, a cationic lipid (Dlin-MC3-DMA), helper lipid (GMO) and PEG-lipid (DMG- or DOPE-PEG) were combined in the ratio of lipid components as shown in Table 1. For example, Dlin-MC3-DMA ranged from 1.5-50%, GMO ranged from 48.5-97% and PEG lipid was maintained at 1.5%. For the aqueous phase, modified mRNA was diluted in citrate buffer, pH 5.5. The aqueous to lipid ratio was 3:1, at a total flow rate of 12 mL/min. After the LNPs were formed, they were dialyzed using 10 mM Tris buffer, pH 7.5 overnight. Post dialysis, 300 mM sucrose was added to stabilize the LNPs and then they were stored at -80°C. Dynamic light scattering was used to determine the particle size which ranged from 114-161 nm with a polydispersity index ranging from 0.10 to 0.15. The encapsulation efficiency was determined using a RNA assay kit and ranged from 42- 94%. RNA integrity was determined by fragment analyzer, using capillary gel electrophoresis and the value for one of the formulations was 80%. The amount of RNA degradation determined from the area of the curve of late migrating species (LMS) and the value of one of the formulations was 6%. Example 2: Glyceryl Monoolein and Cholesterol LNP Formulation-Two Helper Lipids LNPs were formed via microfluidic mixing of an aqueous and lipidic phase, using a Nanoassemblr device. For the lipidic phase, a cationic lipid (Dlin-MC3-DMA), two helper lipids (GMO and cholesterol) and PEG-lipid (DMG- or DOPE- PEG) were combined in the ratio of lipid components as shown in Table 1. For example, Dlin- MC3-DMA ranged from 1.5-50 mol%, GMO ranged from 10-77 mol%, cholesterol ranged from 10-77 mol% and PEG lipid was maintained at 1.5 mol%. For the aqueous phase, modified mRNA was diluted in citrate buffer, pH 5.5. The aqueous to lipid ratio was 3:1, at a total flow rate of 12 mL/min. After the LNPs were formed, they were dialyzed using 10 mM Tris buffer, pH 7.5 overnight. Post dialysis, 300 mM sucrose was added to stabilize the LNPs and then they were stored at -80°C. Dynamic light scattering was used to determine the particle size which ranged from 74-175 nm with a polydispersity index ranging from 0.09 to 0.21. When the cholesterol content was less than 71.4 mol%, LNPs formed within the desired size
range of < 120 nm. The encapsulation efficiency was determined by a RNA assay kit and ranged from 76-99%. RNA integrity was determined by fragment analyzer, using capillary gel electrophoresis and the values ranged from 80-84%. The amount of RNA degradation determined from the area of the curve of late migrating species (LMS) and values ranged from 2-7%. Table 1. Glyceryl monoolein (GMO) lipid nanoparticles (LNPs) investigation, detailing the type of lipid used, the associated composition ratio in mol% and nitrogen to phosphate (N/P) ratio. The corresponding critical quality attributes (CQAs) of lipid nanoparticles are displayed. Data reported as the average of two individual experiments. NA = not available. Glyceryl monoolein (GMO) LNP investigation Criteria 30-120 nm 03 80% 60% 15%
Dlin- GMO:Chol DOPE- 28.5:14.4:55.6:1.5 3.42 74 0.09 99 81 5 MC3- PEG DMA
Example 3: Phytantriol LNP Formulation - One Helper Lipid LNPs were formed via microfluidic mixing of an aqueous and lipidic phase, using a Nanoassemblr device. A different helper lipid, phytantriol (PHY) was used in the formulations. For the lipidic phase, a cationic lipid (Dlin-MC3-DMA), helper lipid (PHY) and PEG-lipid (DMG- or DOPE-PEG) were combined in the ratio of lipid components as shown in Table 2. For example, Dlin-MC3-DMA ranged from 1.5-50 mol%, PHY ranged from 48.5-97 mol% and PEG lipid was maintained at 1.5 mol%. For the aqueous phase, modified mRNA was diluted in citrate buffer, pH 5.5. The aqueous to lipid ratio was 3:1, at a total flow rate of 12 mL/min. After the LNPs were formed, they were dialyzed using 10 mM Tris buffer, pH 7.5 overnight. Post dialysis, 300 mM sucrose was added to stabilize the LNPs and then they were stored at -80°C. Dynamic light scattering was used to determine the particle size which ranged from 97 nm to greater than 1000 nm with a polydispersity index ranging from 0.03 to 1.0. When the amount of PHY was less than 90 mol%, the particle size of the LNPs was less than 300 nm. The encapsulation efficiency was determined by a RNA assay kit and ranged from 77-98%. RNA integrity was determined by fragment analyzer, using capillary gel electrophoresis and ranged from 52-81%. The amount of RNA degradation determined from the area of the curve of late migrating species (LMS) and the value for PHY at 70 mol% was 5%, while it increased to 26% when 48.5 mol% PHY was used in the formulations.
Example 4: Phytantriol and Glyceryl Monoolein LNP Formulation - Two Helper Lipids LNPs were formed via microfluidic mixing of an aqueous and lipidic phase, using a Nanoassemblr device. Two different helper lipids (glyceryl monoolein and phytantriol) were used in the formulations. For the lipidic phase, a cationic lipid (Dlin- MC3-DMA), two helper lipids (GMO and PHY) and PEG-lipid (DMG- or DOPE-PEG) were combined in the ratio of lipid components as shown in Table 2. For example, Dlin-MC3-DMA ranged from 1.5-50 mol%, GMO ranged from 14.4-77 mol%, PHY ranged from 10-77 mol% and PEG lipid was maintained at 1.5 mol%. For the aqueous phase, modified mRNA was diluted in citrate buffer, pH 5.5. The aqueous to lipid ratio was 3:1, at a total flow rate of 12 mL/min. After the LNPs were formed, they were dialyzed using 10 mM Tris buffer, pH 7.5 overnight. Post dialysis, 300 mM sucrose was added to stabilize the LNPs and then they were stored at -80°C. Dynamic light scattering was used to determine the particle size which ranged from 81-140 nm with a polydispersity index ranging from 0.04 to 0.27. The encapsulation efficiency was determined by a RNA assay kit and ranged from 22- 99%. RNA integrity was determined by fragment analyzer, using capillary gel electrophoresis and the values ranged from 53-78%. The amount of RNA degradation determined from the area of the curve of late migrating species (LMS) and values ranged from 4-29%. Table 2. Phytantriol (PHY) and GMO LNPs investigation, detailing the type of lipid used, the associated composition ratio in mol% and nitrogen to phosphate (N/P) ratio. The corresponding critical quality attributes (CQAs) of lipid nanoparticles (LNPs) are displayed. Data reported as the average of two individual experiments. NA =not available. Phytantriol (PHY) and GMO LNP investigation Criteria %)
Dlin-MC3- PHY DMG- 28.5:70:1.5 3.42 90 0.03 97 81 5 DMA PEG Dlin-MC3- PHY DMG- 8.5:90:1.5 1.02 257 0.08 77 NT NA
Example 5: Stability of LNPs at Refrigerated and Ambient Temperatures Exemplary LNPs were chosen based on meeting at least three out of four critical quality attributes, where at least the particle size and RNA integrity meet the desired critical quality attribute criteria. The desired criteria are defined as; particle size < 300 nm, PDI < 0.3, % encapsulation efficiency > 80%, %RNA integrity > 60% and % LMS < 15%. The six exemplary LNP formulations (GMO 70 mol%, GMO:Chol 14.4:55.6 mol%, Chol:GMO 20:77 mol%, PHY 70 mol%, GMO:PHY 14.4:55.6 mol% and PHY:GMO 14.4:55.6 mol%) were all prepared at a larger scale (6 g) and aliquoted into 500 µL tubes. Samples were split across controlled temperature conditions (5°C and 25°C) at ambient humidity, mimicking refrigerator and room temperature, respectively. At designated timepoints of 0, 7, 14 days as well as 1, 2 and 3 months,
an individual sample was removed and tested for particle size, polydispersity, RNA encapsulation and RNA integrity. From both investigations, the six exemplary LNPs were taken into stability studies to assess the CQAs over a period of time at 5°C and 25°C (see Figure 1). Example 6: Morphology of LNPs Cryo-electron microscopy (EM) was used to visualize the morphologies of the lipid nanoparticles. First, a 3 µL sample of LNPs was applied to a Lacey carbon, 300mesh, Au grid then blotted in a controlled environment (5°C, 100%) for 60 seconds and then plunged into liquid nitrogen cooled liquid ethane to vitrify. The morphologies of the LNPs were different amongst formulations. The standard DSPC: cholesterol (10:38.5 mol%) LNPs had irregular spherical-like structures with occurrences of “blebs” from the particle surfaces (Error! Reference source not found.A). This structural morphology has previously been reported on by Yanez Arteta et al. (PNAS 2018, 115:E3351). Standard DSPC: cholesterol LNPs also had distinctive shell layer on the particles, indicative of a lamellar-type bilayer. In comparison, 70 mol% GMO LNPs population were spherical and densely packed within the core as observed by the darker colored particles in Error! Reference source not found.B. GMO: cholesterol (14.4:55.6 mol%) LNPs were less dense in color, but had particle populations with well-defined straight edges, similar to hexagonal shapes, as demonstrated by the white box outlines in Error! Reference source not found.C. The core of these particles was similar in density to the shell, showing uniformity throughout the particle. Increasing the GMO content and decreasing the cholesterol content (i.e. cholesterol: GMO 22:77 mol% LNPs) resulted in “bleb” formation, with the inability to distinguish between single particle morphologies, as observed in Error! Reference source not found.D. PHY 70 mol% LNPs were again different to GMO 70 mol% LNPs, where particles had both cubic-like shapes (red boxes) as well as uniquely defined graph lines within the core (black boxes, Error! Reference source not found.E). For PHY:GMO 14.4:55.6 mol% LNPs, the density increased with the occurrence of the cubic shaped particles (Error! Reference source not found.F). The dense cubic shaped particles observed for PHY:GMO 14.4:55.6 mol% is further indicative of improved thermostability at 5°C and 25°C.
Example 7: Morphology of LNPs – Small Angle X-ray Scattering Small angle x-ray scattering (SAXS) experiments were conducted on Brookhaven National Laboratories National Synchrotron Light Source II. LNPs were measured in glass capillaries with a sample to detector distance of 3.687 m, giving a q range 0.005 to 3.1 Å-1. The wavelength of the X-rays λ was 0.8206 Å. The intensity versus q graphs were plotted to determine the index spacing of major peaks in order to correlate global structural configurations of the LNPs. SAXS diffractograms in Error! Reference source not found. highlight peaks indexed 1, 2 and 3 spacings for DSPC:Cholesterol 10:37.5% LNPs, indicative of the lamellar phase. Increasing the amount of DSPC:Cholesterol to 14.4:55.6% in the LNPs, while decreasing the cationic lipid, MC3, resulted in a shift of the Bragg peaks to 1, √3 and 2 spacings in Figure 3A, highlighting a phase shift to the inverse hexagonal phase. When GMO replaced DSPC, forming GMO:Chol 10:37.5% LNPs, the inverse hexagonal phase was also demonstrated by Bragg peaks at the 1:√3:2 spacing ratio (Figure 3A). A similar shift to Bragg peaks at spacing ratio 1:√3:2, was observed in Figure 3 for when PHY replaced DSPC, forming PHY:Chol 10:37.5% LNPs. When the ratio of GMO:Chol was increased to 14.4:55.6% and the MC3 was decreased, another shift occurred compared to the standard DSPC:Chol, where a broad Bragg peak was observed at :√3 (Figure 3B). This broad peak could not be resolved into single peaks but is expected to contain multiple peaks, indicative of the inverse bi-continuous cubic phase, where the lipid bilayers display triply periodic minimal surface geometry and interweaved between two connecting water channels (Meikle T.G. et al. Colloids and Surfaces B: Biointerfaces, 152, pp.143-151 (2017)). This structure represents a tightly packed arrangement of lipids. A similar diffractogram indicative of the bi-continuous cubic phase was also observed for three-component system using GMO as the structural lipid, at 47.5% and 70% mole ratio. For PHY based systems, increasing the amount of PHY:Chol to 14.4:55.6 %mol maintained an inverse hexagonal phase structure. However, a three-component PHY system at 47.5%mol and 70%mol had diffractograms that shifted to a broad peak at : √3, suggesting a transition to the inverse bi-continuous cubic phase. Example 8: Morphology of LNPs – NMR and Cryo-EM
The one-dimensional proton nuclear magnetic resonance (1D 1H NMR) spectra of different LNPs is displayed in Figure 4, and provides information on the chemical identity of the surface lipids of the LNPs. Samples were measured as intact LNPs. Samples were diluted with 0.2M x DPBS, and spiked 10% D2O, 0.05% trisodium phosphate. Different excitation sculpting pulse sequences were used to render the 1D 1H NMR spectra including; (1) 1d1H, sequence: zgesgp -H 90 degree pulse and (2) 1d1H, sequence: PGSTE (stebpesgp1s1d) - T2 filter to suppress excipients signal. Surface PEG methylene signals are well resolved on the surface of all LNPs. LNPs with PHY 70%mol (#149) and GMO:PHY 14.4:55.6%mol (#150) show very similar surface lipid profiles, likely attributable to the fact that similar amount of PHY are within the formulation. Similarly, LNPs with GMO 70% (#146) and PHY:GMO 14.4:55.6% (#151) also show very similar surface lipid profiles, for the same reason as PHY, and differ in peak positions only by the chemical shifts of GMO compared to PHY. LNPs with GMO:Chol 14.4:55.6%mol (#147) distinctly shows surface lipid profiles with significantly lowest peak intensity (Figure 3). It suggests the less mobile surface lipids and likely a more rigid particle. Electron microscopy (EM) shows particles that have stripe patterns that may be caused by the combination of GMO and cholesterol. In Figure 4A, the EM also demonstrated that many particles in this sample are slightly cubic in shape (arrow), which corresponds with the SAXS diffractograms. GMO and cholesterol play a role as structural lipids such that the higher amount of cholesterol (55.6%mol) combined with GMO promotes the particle shape to change. For LNPs with GMO:Chol 22:77%mol (#148), there is a smaller PEG-methylene peak at 3.8 ppm that is likely associated with surface PEG changes (Figure 4). This peak correlates to the high abundance of blebs observed in EM images in Figure 5B. Both high levels of glyceryl monooleate and cholesterol likely contribute to bleb formation. Example 9: LNP Cell Uptake and Cytoplasmic Distribution Hela cells were seeded (1×104 cells/well) in 96 well plates and incubated with mRNA-LNPs. At a variety of time points (1 h, 4 h and 24 h), different quantification techniques were used to determine LNP (1) uptake/association, (2) internalization and (3) mRNA translation. For mRNA-LNP uptake/association, quantitative reverse transcription polymerase chain reaction (RT-qPCR) was employed to quantify the
amount of mRNA within the cell after 1 h and 4 h of incubation. For mRNA internalization into the cytoplasm (i.e. release from the endosome), single-molecule Fluorescence in situ Hybridization (smFISH) was used at 4 h and 24 h post incubation. Lastly, for mRNA translation, a standard immunofluorescence assay was used to determine the total cell count, the amount of HA positive cells and the mean fluorescence intensity, 24 h post incubation with mRNA-LNPs, where the mRNA encoded for the HA- influenza virus protein. For LNP cell uptake, GMO:Chol (14.4:55.6 [denoted as 207]) LNPs rapidly associated with the cell, where up to approximately 4x107 HA copies were quantified within the cell 1h post transfection, as demonstrated in Figure 6. This was equivalent to the standard LNP control, DSPC:Chol (10:37.5 [denoted as 198]) LNP. For both of these LNPs the cellular uptake/association was retained at the same level at 4 h post transfection. There was a minimum of 0.5x107 HA copies quantified for Chol:GMO (22:77%)/208 LNP at 1 h and 4 h, indicating potential cell association, although this was close to the limit of detection. For other LNPs, including GMO (70%)/#205, PHY (70%)/#206, GMO:PHY (14.4:55.6)/#209 and PHY:GMO (14.4:55.6)/#210, minimal to no cell association of mRNA was detected. In the next step of the transfection process, cellular internalization of the mRNA- LNPs by imaging cytoplastic distribution was examined at 4 h and 24 h post transfection. At 4 h, out of the six LNPs tested, only the standard LNP, DSPC:Chol (10:37.5%)/198 resulted in cytoplasmic distribution of the mRNA, quantified as 50% modRNA positive cells (Figure 7A), with approximately 40 mRNA positive spots per cell (Figure 7B). Following 24 h, the amount of mRNA distributed within the cytoplasm remained consistent per cell for the standard LNP. However, the cytoplasmic distribution of mRNA increased from GMO:Chol (14.4:55.6%)/#207 LNP, with less than 5% modRNA positive cells (Figure 7C), and approximately 5 mRNA positive spots per cell (Figure 7D). This indicated a slower internalization of mRNA from GMO:Chol (14.4:55.6)/#207 LNPs compared to the standard LNP control. Further time points were not taken to continue this observation. All other LNPs did not demonstrate any cytoplasmic distribution at 4 h or 24 h. Consequently, a dose response transfection was only observed with DSPC:Chol (10:37.5%)/#198 LNP between 0.39 and 100 ng mRNA-LNP, with an EC50 of approximately 9 ng, as observed from the percentage of positive HA antigen and mean fluorescence intensity graphs in Figure 8A and B, respectively. All other LNPs
did not demonstrate any response at 24 h post transfection. The limited response is likely related to the limited cytoplasmic distribution of the novel LNPs at 4 h post transfection. While GMO:Chol (14.4:55.6%)/#207 LNP began to distribute within the cytoplasm at 24 h, the level of mRNA is unlikely sufficient to drive translation to HA protein. While the response was not measured beyond 24 h, it is suggested that longer transfection periods may enable a response from the GMO:Chol (14.4:55.6%) LNP. Cell viability was sequentially assessed during the transfection assay by determine the number of cells remaining post 24 h incubation. LNPs containing GMO:Chol 14.4:55.6 (207), Chol:GMO 22:77 (208), and GMO:PHY 14.4:55.6 (209) were less cytotoxic at higher concentrations (≥12.5 ng) compared to the standard LNP DSPC:Chol 10:37.5 (198) (Figure 8C).
Claims
CLAIMS We Claim: 1. A lipid nanoparticle (LNP) comprising: (a) at least one nucleic acid; (b) at least one polymer-lipid conjugate in an amount from about 0.05 to about 5 mol% of the total lipid in the particle; (c) at least one cationic lipid in an amount from about 0.1 to about 50 mol% of the total lipid in the particle; and (d) at least one structural lipid selected from a monoacylglycerol and an aliphatic alcohol, wherein each of said at least one structural lipids is present in an amount from about 10 to about 99 mol% of the total lipid in the particle.
2. The LNP of claim 1, wherein the at least one polymer-lipid conjugate is a polyethylene glycol (PEG)-lipid conjugate.
3. The LNP of claim 2, wherein the PEG-lipid conjugate is present in an amount of about 1.5 mol% of the total lipid in the particle.
4. The LNP of claim 2, wherein the PEG-lipid conjugate is selected from: dimyristoylphosphatidylcholine-polyethylene glycol-2000 (DMPC-PEG); 1,2- dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG); 1,2-dioleoyl- sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] ammonium salt (DOPE-PEG); 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-poly (ethylene glycol)-2000 (DSPE-PEG); mPEG-N,N-ditetradecylacetamide (ALC-0159); and oleoyl polyethylene glycol 2000.
5. The LNP of claim 1, wherein the at least one cationic lipid is present in an amount from about 10 to about 20 mol% of the total lipid in the particle.
6. The LNP of claim 1, wherein the at least one cationic lipid is selected from: (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (Dlin-MC3-DMA); [(4-hydroxybutyl)azanediyl]di(hexane-6,1-diyl) bis(2- hexyldecanoate) (ALC-0315); 2-[2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1,3-dioxolan-
4-yl]-N,N-dimethylethanamine (DLin-KC2-DMA); 1,2-dilinoleyloxy-n,n-dimethyl-3- aminopropane (DLinDMA); N,N-dimethyl-2,3-bis[(Z)-octadec-9-enoxy]propan-1- amine (DODMA); 5-carboxyspermylglycinedioctadecylamide (DOGS); and 1,2- dioleoyl-3-dimethylammonium-propane (DODAP).
7. The LNP of claim 6, wherein the at least one cationic lipid is Dlin-MC3-DMA.
8. The LNP of claim 1, wherein the at least one structural lipid is glyceryl monoolein (GMO).
9. The LNP of claim 1, wherein the at least one structural lipid is phytantriol (PHY).
10. The LNP of claim 1, comprising at least one monoacylglycerol structural lipid and at least one aliphatic alcohol structural lipid.
11. The LNP of claim 10, wherein the monoacylglycerol is GMO.
12. The LNP of claim 10, wherein the aliphatic alcohol is PHY.
13. The LNP of claim 1, further comprising at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol, wherein said at least one additional structural lipid is present in an amount from about 10 to about 75 mol% of the total lipid present in the particle.
14. The LNP of claim 13, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 14.4 mol%; the at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol is cholesterol and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DOPE-PEG and is present in an amount of about 1.5 mol%.
15. The LNP of claim 13, wherein: the at least one cationic lipid is present in an amount of about 1.5 mol%; the at least one structural lipid is GMO and is present in
an amount of about 77 mol%; the at least one additional structural lipid that is not a monoacylglycerol or an aliphatic alcohol is cholesterol and is present in an amount of about 20 mol%; and the at least one polymer-lipid conjugate is DOPE-PEG and is present in an amount of about 1.5 mol%.
16. The LNP of claim 1, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is PHY and is present in an amount of about 70 mol%; and the at least one polymer-lipid conjugate is DMG- PEG and is present in an amount of about 1.5 mol%.
17. The LNP of claim 1, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 14.4 mol%; a second structural lipid is PHY and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DOPE- PEG and is present in an amount of about 1.5 mol%.
18. The LNP of claim 1, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is PHY and is present in an amount of about 14.4 mol%; a second structural lipid is GMO and is present in an amount of about 55.6 mol%; and the at least one polymer-lipid conjugate is DMG-PEG and is present in an amount of about 1.5 mol%.
19. The LNP of claim 1, wherein: the at least one cationic lipid is present in an amount of about 28.5 mol%; the at least one structural lipid is GMO and is present in an amount of about 70 mol%; and the at least one polymer-lipid conjugate is DOPE- PEG and is present in an amount of about 1.5 mol%.
20. The LNP of any one of claims 1-19, wherein the nucleic acid is DNA, plasmid DNA, minicircle DNA, ceDNA (closed ended DNA), siRNA, mRNA, miRNA, self- replicating RNA, CRISPR RNA, a gene editing construct, an RNA editing construct, a base editing construct, or a prime editing construct.
21. The LNP of any one of claims 1-19, wherein the at least one nucleic acid is mRNA.
22. A pharmaceutical composition comprising the LNP of any one of claims 1-21, and a pharmaceutically acceptable carrier.
23. The pharmaceutical composition of claim 22, which is formulated for intravenous administration.
24. A method for delivering a nucleic acid to a cell comprising contacting the cell with the LNP of any one of claims 1-21, or the pharmaceutical composition of any one of claims 22-23.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263375898P | 2022-09-16 | 2022-09-16 | |
US63/375,898 | 2022-09-16 | ||
US202363513983P | 2023-07-17 | 2023-07-17 | |
US63/513,983 | 2023-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024057237A1 true WO2024057237A1 (en) | 2024-03-21 |
Family
ID=88098230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/059101 WO2024057237A1 (en) | 2022-09-16 | 2023-09-13 | Lipid nanoparticles |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024057237A1 (en) |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040142025A1 (en) | 2002-06-28 | 2004-07-22 | Protiva Biotherapeutics Ltd. | Liposomal apparatus and manufacturing methods |
US20070042031A1 (en) | 2005-07-27 | 2007-02-22 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
US20160122759A1 (en) * | 2013-05-06 | 2016-05-05 | Alnylam Pharmaceuticals, Inc. | Dosages and methods for delivering lipid formulated nucleic acid molecules |
WO2016118697A1 (en) | 2015-01-21 | 2016-07-28 | Phaserx, Inc. | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
US9737619B2 (en) | 2014-06-25 | 2017-08-22 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US10166298B2 (en) | 2015-10-28 | 2019-01-01 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US20200155691A1 (en) | 2016-11-10 | 2020-05-21 | Translate Bio, Inc. | Ice-based lipid nanoparticle formulation for delivery of mrna |
US20200206362A1 (en) | 2015-12-10 | 2020-07-02 | Moderna TX, Inc. | Compositions and methods for delivery of agents |
WO2020219941A1 (en) | 2019-04-26 | 2020-10-29 | Genevant Sciences Gmbh | Lipid nanoparticles |
US20210046192A1 (en) * | 2019-07-23 | 2021-02-18 | Translate Bio, Inc. | Stable compositions of mrna-loaded lipid nanoparticles and processes of making |
WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
WO2022087686A1 (en) | 2020-10-30 | 2022-05-05 | Royal Melbourne Institute Of Technology | Lyotropic liquid crystalline phase particle |
-
2023
- 2023-09-13 WO PCT/IB2023/059101 patent/WO2024057237A1/en unknown
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040142025A1 (en) | 2002-06-28 | 2004-07-22 | Protiva Biotherapeutics Ltd. | Liposomal apparatus and manufacturing methods |
US20070042031A1 (en) | 2005-07-27 | 2007-02-22 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
US20160122759A1 (en) * | 2013-05-06 | 2016-05-05 | Alnylam Pharmaceuticals, Inc. | Dosages and methods for delivering lipid formulated nucleic acid molecules |
US9737619B2 (en) | 2014-06-25 | 2017-08-22 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2016118697A1 (en) | 2015-01-21 | 2016-07-28 | Phaserx, Inc. | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
US10166298B2 (en) | 2015-10-28 | 2019-01-01 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US20200206362A1 (en) | 2015-12-10 | 2020-07-02 | Moderna TX, Inc. | Compositions and methods for delivery of agents |
US20200155691A1 (en) | 2016-11-10 | 2020-05-21 | Translate Bio, Inc. | Ice-based lipid nanoparticle formulation for delivery of mrna |
WO2020219941A1 (en) | 2019-04-26 | 2020-10-29 | Genevant Sciences Gmbh | Lipid nanoparticles |
US20210046192A1 (en) * | 2019-07-23 | 2021-02-18 | Translate Bio, Inc. | Stable compositions of mrna-loaded lipid nanoparticles and processes of making |
WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
WO2022087686A1 (en) | 2020-10-30 | 2022-05-05 | Royal Melbourne Institute Of Technology | Lyotropic liquid crystalline phase particle |
Non-Patent Citations (29)
Title |
---|
"Final Report on the Safety Assessment of Phytantriol", INT. J. TOXICOL, vol. 1, 2007, pages 107 - 114 |
AKINC ET AL., NATURE BIOTECHNOLOGY, vol. 26, 2008, pages 561 - 569 |
BAIGUDE ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 107, 2005, pages 276 - 287 |
BARAUSKAS ET AL., LANGMUIR, vol. 19, pages 9562 - 9565 |
EYGERIS ET AL., NANO LETT, vol. 20, no. 6, 2020, pages 4543 - 4549 |
EYGERIS ET AL., NONO LETTERS, vol. 20, 2020, pages 4543 |
GOMEZ-AGUADO ET AL., NANOMATERIALS, vol. 10, no. 2, 2020, pages 364 |
GRUNWITZKRANZ: "Current Topics in Microbiology and Immunology", vol. 405, 2017, SPRINGERLINK, article "mRNA Cancer Vaccines - Messages that Prevail" |
H. KIMC. LEA, ACS NANO, vol. 9, no. 10, 2015, pages 10214 - 10226 |
HAN ET AL., NAT COMMON, vol. 12, 2021, pages 7233 |
J.H. LEE ET AL., NATURE, vol. 609, 2022, pages 998 - 1004 |
KAASGAARD ET AL., PHYS CHEM CHEM PHYS, vol. 8, no. 43, 2006, pages 4957 - 75 |
KOPPEL, D, J. CHEM. PHYS, vol. 57, 1972, pages 4814 - 4820 |
LIANG ET AL., MOI. THER, vol. 25, 2017, pages 2635 - 2047 |
LIU ET AL., J. CONTROLLED RELEASE, vol. 345, 2022, pages 306 - 313 |
LOVE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 107, 2010, pages 1864 - 1869 |
MEIKLE T.G ET AL., COLLOIDS AND SURFACES B: BIOINTERFACES, vol. 152, 2017, pages 143 - 151 |
NARAYANAN ET AL., J. IMMUNOTHER CANCER, vol. 11, 2023, pages e006133 |
OU ET AL., ADV. DRUG DEL. REV, vol. 187, 2022, pages 11401 |
PARDI ET AL., J. CONTROL. RELEASE, vol. 217, 2015, pages 345 - 351 |
ROBBINS ET AL., OLIGONUCLEOTIDES, vol. 19, 2009, pages 89 - 102 |
ROZEMA ET AL., PROC NATL ACAD SCI USA., vol. 104, 2007, pages 12982 - 12887 |
SCHOENMAKER ET AL., INT. J. OF PHARMACEUTICS, vol. 601, 2021, pages 120586 |
SEMPLE ET AL., NATURE BIOTECHNOLOGY, vol. 28, 2010, pages 172 - 176 |
SULLIVAN ET AL., EXPERT OPIN DRUG DELIV, vol. 20107, pages 1433 - 1446 |
YANEZ ARTETA ET AL., PNAS, vol. 115, 2018, pages E3351 |
ZHAI JIALI ET AL: "Non-Lamellar Lyotropic Liquid Crystalline Lipid Nanoparticles for the Next Generation of Nanomedicine", ACS NANO, vol. 13, no. 6, 13 May 2019 (2019-05-13), US, pages 6178 - 6206, XP055937802, ISSN: 1936-0851, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acsnano.8b07961> DOI: 10.1021/acsnano.8b07961 * |
ZILLER ET AL., MOL. PHARMACEUTICS, vol. 15, no. 2, 2018, pages 642 - 651 |
ZIMMERMANN ET AL., NATURE, vol. 441, 2006, pages 111 - 114 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5977394B2 (en) | Interfering RNA encapsulated in lipid | |
US9926560B2 (en) | Lipid encapsulating interfering RNA | |
JP4764426B2 (en) | Cationic lipids and methods of use | |
US20120264810A1 (en) | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles | |
US11938227B2 (en) | Lipid nanoparticles encapsulation of large RNA | |
WO2024057237A1 (en) | Lipid nanoparticles | |
WO2024062001A1 (en) | Lipid nanoparticle with nucleic acid cargo | |
NZ583623A (en) | Lipid encapsulated interfering RNA |